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           Summary of Thesis: 
 
Optimising the psoriasis care pathway is a multifaceted process that requires input from all 
healthcare professionals involved in psoriasis patient care. At the primary healthcare level 
GPs should be more aware of the impact of psoriasis on patients’ lives and use a validated 
quality of life instrument to measure this impact and ideally to improve the triage of psoriasis 
referrals to secondary care. One of the studies presented in this thesis shows a potential 
benefit of utilizing the Dermatology Life Quality Index (DLQI) as a triage tool to identify those 
individuals experiencing the greatest impact on their quality of life. Systemic therapies for 
psoriasis should be selected on a case by case basis according to guidelines, patients’ 
comorbidities and their personal preferences. It is important that patients are fully aware of 
the available evidence to enable them to make informed decisions. Fumarates are one of 
the recognised systemic therapies for psoriasis. The Cochrane systemic review presented 
in this thesis demonstrates its superiority over placebo and possibly similar efficacy to 
methotrexate; however these findings were based on low-quality evidence. Following the 
Cochrane review publication, dimethylfumarate was licensed by the European Medicines 
Agency (EMA) based on new trial evidence and approved by the National Institute for 
Health and Care Excellence (NICE) as a third line systemic therapy for moderate-to-severe 
psoriasis. There is growing evidence that continued improvement on fumarates occurs after 
the usual 12 – 16 week endpoints commonly used in psoriasis trials. Therefore, long-term 
randomised clinical trials are needed to measure their true effect and safety in direct head-
to-head comparisons with other systemic treatments. Inclusion of fumarates in 
pharmacovigilance databases will be important to assess rare, delayed adverse effects 
such as progressive multifocal leukoencephalopathy.  
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CHAPTER 1 
Introduction 
 
 
 
Background 
 
The United Kingdom (UK) population in 2015 was estimated to be 65,110,000 and only 
4.76% of those live in Wales (1). The Office for National Statistics reported an annual 
increase in the population by 0.8% a year for the past decade. This, along with the fact that 
people live longer, will eventually lead to further strains on public services, including the 
National Health Service (NHS).  
 
Skin complaints are amongst the most common medical problems in the UK population. 
Population-based surveys have shown that around 54% of the population experience a skin 
condition each year (2). Interestingly, only 14% of those seek medical advice whereas the 
majority opt for self-medication. Despite this, skin conditions remain the top reason for 
General Practitioner (GP) new appointments with nearly 13 million consultations in 2006 of 
which 6.1% of these were referred to specialists. This demand is stretching available 
healthcare resources. The total number of doctors on the GP register in November 2016 was 
61,140 representing one GP per 1,065 population (3) compared to approximately one 
dermatologist per 100,000 population (4). In comparison with other countries, the density of 
dermatologists in the UK remains lower than in the United States of America (USA) (3.4 
dermatologists per 100,000 population) (5); Saudi Arabia (3.76 dermatologists per 100,000 
population) (6); Australia (2.1 dermatologists per 100,000 population) (7) 
 
What is more, the health care service model in the UK is different from other countries. 
Whereas patients can access a specialist directly in other countries, in the UK they need to 
be referred by GPs, who are the first-line contact and represent the gate-keepers to 
secondary care access. Yet, dermatology training is not compulsory in postgraduate GP 
training, and very minimal in undergraduate studies. As a result, the quality of dermatology 
services provided in primary care may not be ideal which can influence the appropriateness 
of referrals to secondary care. For instance, patients who require a specialist input may not 
be referred in a timely fashion and so endure severe skin disease whereas others with mild 
or benign conditions are referred which results in increased pressure and waiting times in 
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secondary care. There is a lack of robust studies to measure the quality of dermatology 
services in primary care.  
 
The choice of systemic therapies provided in secondary care can be a challenge to patients 
and clinicians. Patients should be informed of the pros and cons of available treatment 
options to be able to make an informed decision in partnership with the treating clinician. 
Therefore, high quality evidence data is needed to facilitate the process of decision making, 
especially as health economics is becoming increasingly influential in dermatology 
commissioning and funding decisions (8).  
 
 
Psoriasis: An overview 
 
Psoriasis is a chronic inflammatory skin disease. It was thought to be a form of leprosy for 
hundreds of years until 1809 when Dr Robert Willan first recognised psoriasis as a distinct 
entity and described it accurately (9). Ferdinand Hebra (1816-1880) eliminated the term 
‘lepra’ (10). Since then our knowledge about psoriasis has come along way mainly due to 
advancements in translational research in the past few decades.  
 
Psoriasis can be divided into a number of clinical subtypes. The most common subtype is 
chronic plaque psoriasis, which presents as well-defined erythematous, scaly plaques 
typically on the elbows, knees, and scalp (Figure 1). Other subtypes include flexural 
(inverse) psoriasis, in which erythematous patches are located in the skin creases (Figure 
2); guttate psoriasis, in which there are multiple small plaques, particularly on the trunk 
(Figure 3); generalised pustular psoriasis, involving multiple skin pustules (Figure 4); and 
erythrodermic psoriasis covering nearly all of the skin surface (Figure 5) (11). Palmoplantar 
pustulosis, characterised by inflammation and sterile pustules on the palms of the hands and 
the soles of the feet, is still debatable whether it is a varient of psoriasis or a separate entity. 
Psoriasis is usually diagnosed based on typical clinical features; a skin biopsy can also be 
helpful if there is diagnostic uncertainty. Psoriatic nail changes, including onycholysis and 
nail pitting, are observed in about 40% of people with psoriasis (12). Psoriatic arthritis (PsA) 
is a recognised comobidity of psoriasis, observed in 6% - 42% of cases in population based 
studies, depending on the definitions used (13).   
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Figure 1: Chronic plaque psoriasis (from 
Griffiths and Barker (14)). 
 
 
Figure 2: Inverse psoriasis (from Griffiths and 
Barker (14)). 
 
 
Figure 3: Guttate psoriasis (from Lebwohl 
(11)). 
 
Figure4: Generalised pustular psoriasis (from 
Lebwohl (11)). 
 
 
 
Figure 5: Erythrodermic psoriasis (from 
Lebwohl (11)). 
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Epidemiology: 
 
Psoriasis occurs worldwide and has a higher prevalence in countries further from the 
equator (15). In the UK, it affects about 1.5-2% of the population (16, 17). Psoriasis can 
develop at any age; the mean age of onset may have two peaks, with the first in young 
adults and a second peak in about the sixth decade of life (18). Data from the General 
Practice Research Database (GPRD) on 114,521 patients with psoriasis showed the 
prevalence in children under 10 years of age to be less common, at 0.55% (17). This study 
showed the prevalence rates increased with age in a linear fashion. A similar trend of 
prevalence has been reported in a German study based on health insurance data (19). 
Psoriasis appears to affect men and women about equally (14, 17).  
 
Pathogenesis: 
 
The pathogenesis of psoriasis is complex and has attracted a great amount of research in 
the past few decades. It is now believed that a combination of genetic, immunological and 
environmental factors contribute to the phenotype of psoriasis (20).  
 
Genetic factors: 
Studies have indicated genetic contributions to psoriasis. A family history of psoriasis 
increases the risk of developing the condition. It has been observed that about a third of 
psoriasis patients have an affected first degree relative (21). The risk of psorasis in 
monozygotic twins is two to three times greater than in dizygotics twins (22). However, 
psoriasis in one identical twin does not always predict psoriasis in the other (23). The mode 
of inheritence is complex and appears polygenic (21). Mendelian pattern of inheritence is 
only observed in a small minority of families, whereas most of the posriasis population have 
multiple genetic risk factors interacting with each other and with environmental triggers 
leading to disease development (24). Genetic studies have identified several chromosomal 
loci (PSORS1-9) linked to the development of psoriasis (25). The major one is PSORS1 
gene, located on chromosome 6, which accounts for 35-50% of the disease heritability (26). 
Genetic heterogeneity has been demonstrated in clinical varients of psoriasis. For example 
guttate psoriasis is strongly associated with PSROS1 whereas this association was lacking 
in palmoplantar pustulosis and in psoriasis starting in persons over 50 years of age (27, 28). 
 
Environmental factors: 
Environmental exposures can precipitate psoriasis in some cases, such as Streptococcus 
pyogenes throat infections leading to guttate psoriasis (29), and medications, including beta-
blockers, lithium and synthetic antimalarial drugs, may trigger or aggravate chronic plaque 
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psoriasis (30). Skin trauma (e.g. due to surgery) can trigger psoriasis at the surgical site, an 
observation known as the Koebner phenomenon (14). In a prospective cohort study based 
on the GPRD, smoking has been reported as independent risk factor for psoriasis (odds ratio 
(OR) 1.4 [95% confidence interval (95%CI) 1.3 to 1.6]) (31).  
 
Keratinocytes and the innate immune system: 
Until the early 1980’s, psoriasis was thought to be a disease of epidermal keratinocyte 
proliferation. In 1984, Baker et al (32) proposed that psoriasis results from interaction 
between T helper (Th) cells with antigen-presenting cells in the epidermis. This theory was 
supported by reports of psoriasis clearance after allogenic bone marrow transplantation (33) 
and immune supression by cyclosporin A (34-36). It has been suggested that psoriasis 
evolves due to interplay between cells and mediators of the innate and adaptive immune 
system (37). Dysregulation of the innate immune system has been shown in psoriasis (38). 
Plasmacytoid dendritic cells, which are producers of interferon-a, are increased and 
activated in psoriatic lesions. Keratinocytes in psoriatic lesions are rich of antimicrobial 
peptides (AMP) which can have a chemotactic role and shape the function of dendritic cells 
and T cells (39).  
 
Dendritic cells and cytokines: 
Dendritic cells (DC) are key players in the pathogenesis of psoriasis; DC activated by 
various stimuli secrete tumour necrosis factor-a (TNF-a), interleukin (IL)-23 and IL-12. IL-23 
induces differentiation of naive T cells into Th17 which in turn produce IL-17 and IL-22. TNF-
a and IL-17 activate keratinocytes, promote epidermal hyperplasia, recruit inflammatory 
cells, such as neutrophils, and induce AMP production. IL-12 produced by DC also induces 
Th1, which then produces cytokines, including INF-g. This immune cascade continues as 
TNF-a activates dendritic cells (Figure 6). Understanding this pathway has led to the 
development of targeted therapies that inhibit specific steps in the inflammatory cascade, 
such as TNF-a, IL-12/23, and recently, IL-17 (40).  
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Figure 6: Main immunologic pathway in the pathogenesis of psoriasis. IFN: interferon; IL: 
interleukin; TNF: tumour necrosis factor (from Ogawa et al, 2017 (40)).  
 
T-cells: 
For a number of years psoriasis was believed a Th1 mediated disease as the expression of 
Th1 cytokines, such as g-interferon (INF-g), TNF-a and IL-12, were observed in psoriatic 
lesions while there was no such increase of Th2 cytokines (41-43). However, other factors 
are thought to play a role in the disease development as epidermal keratinocyte proliferation 
is not induced by these cytokines (44, 45). The aforementioned roles of Th-17 released 
cytokines, namely IL-17 and IL-22,  have led to the believe that Th-17 is a key element in 
psoriasis development (20). This was further supported by the reduction of Th-17 during 
successful anti-TNF treatment (46).  
 
In addition, tissue samples have demonstrated that new blood vessel formation is a 
characteristic finding within psoriatic plaques, so angiogenic mediators, such as vascular 
endothelial growth factor, represent another potential psoriasis pathway (47).  
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Psoriasis severity assessment: 
 
In 2013, the International Dermatology Outcome Measures (IDEOM) group was established 
to address the need for standardised patient-centred clinical outcome measures to assess 
disease course and response to treatment in clinical trials and clinical practice (48). This has 
led to the development of Core Outcome Sets (COSs); a consensus-driven minimum set of 
outcomes of a specific condition that must be measured and reported in a clinical trial (49). 
This is aimed to enable comparison and combination of results across trials, attempt to 
reduce selective outcome reporting bias and increase clinical interpretability (50).  
 
Callis Duffin and colleagues (51) have recently published the results of an iterative Delphi 
process to identify a core domain set to assess psoriasis in clinical trials. The Delphi process 
stakeholders involved patients or advocates of patients with psoriasis and health care 
professionals (HCP) with expertise in psoriasis, including physicians, scientists, advocacy 
organisation representatives, and regulators. Most HCP were dermatologists (67%) from 
North America (57%) and Europe (32%). A domain was considered ‘core’ if a threshold 
consensus of at least 70% was met in both patient and HCP whereas domains meeting 
consensus in only one group were considered to be important but not required to be 
measured in all trials. Six core domains were identified, including: skin manifestations, 
psoriasis and psoriatic arthritis symptoms, health-related quality of life, investigator global 
assessment, patient global assessment, and treatment satisfaction (Figure 7).  
 
Figure 7: Onion model of core domains for psoriasis clinical trials. The inner (left ring) includes 
the 6 core domains that are considered required to measure in every psoriasis clinical trial. The 
middle ring includes 1 domain (skin manifestations) with 5 subdomains that are not required but may 
be important depending on the study objectives. The outer ring (right) includes 4 domains that are 
considered the “research agenda,” or items that may be important but need further study. BSA: body 
surface area (From Callis Duffin et al (51)). 
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Assessment of psoriasis severity is important to determine appropriate treatment for 
individual patients and for assessment of response to treatment. Disease severity can be 
assessed by physical findings, such as body surface area (BSA) involved, distribution, and 
degrees of erythema and scaling. These parameters can be measured by using the 
Psoriasis Area and Severity Index (PASI), which is the current gold standard for the physical 
signs domain of psoriasis severity (52). Nevertheless, this does not indicate the effect of 
disease on a patient’s social life, self-perception and physical discomfort.  
 
There are different ways of obtaining information regarding patients’ QoL, including face to 
face interviews, telephone interviews, focus groups and questionnaires. Interviews and focus 
groups, although valuable in providing rich data, are time consuming, expensive and are less 
likely to be practical in a clinical setting. On the other hand, a more common and practical 
approach to measuring QoL is by the use of questionnaires. Standardised questionnaires for 
self-rating by the respondents are very useful for recording QoL not only because of their 
ease of use but also being quicker and allowing data recording independent of the 
investigator thus avoiding the influence of the questioner on the respondent (53).  
 
A number of validated dermatology-specific QoL questionnaires exist. Some of these are 
disease-specific, such as: 
- Cardiff Acne Disability Index (54) 
- Psoriasis Disability Index (PDI) (55). This is a self-adminstered 15 item psoriasis 
specific questionnaire with five subscales: daily activities, work, personal relations, 
leisure and treatment. 
 
Other tools are not disease-specific and can be used in different skin conditions. These 
include:  
- Dermatology-Specific Quality of Life Instrument (56); a self-completed 52-item 
questionnaire with domains on physical discomfort and symptoms, psychological 
well-being, social functioniong, self-care activities, performance at work or school, 
and self-perceptions. 
- Skindex-29 (57, 58); a self-adminstered 29-item questionnaire with three domains: 
functioning, emotions and symptoms.  
- Dermatology Life Quality Index (DLQI) (59); a self-completed 10-item questionnaire 
which covers symptoms and feelings, daily activities, leisure, work and school, 
personal relationship, and treatment.  
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Another tool, Medical Outcome Study Short Form 36 (SF-36) (60), is not a dermatology-
specific, self-administered questionnaire of 36 items in eight subscales groups in two 
domains, physical and mental. Similarly, EuroQoL five dimensions (EQ-5D) is a nonspecific 
self-reported instrument used to measure health outcomes or general health status which is 
validated for use across a wide range of conditions (61). This tool covers five dimensions of 
the responder’s perceived problems including mobility, salf-care, usual activities, 
pain/discomfort, and anxiety. Each dimension contains five descriptors and the patient 
selects the one which best describes the extent of their problem. The descriptors are 
converted into numerical values resulting a five-digit health profile. Each profile is associated 
with a single utility index value ranging from 0 (= dead) to 1 (= full health) (61).  
 
A recent systematic review by Ali et al (62) examined the use of QoL instruments in 
ranomised controlled trials (RCTs) for psoriasis. This demonstrated that the DLQI was the 
most widely used instrument (83%), followed by SF-36 (31%), EuroQoL-5D (15%), PDI 
(14%) and Skindex (5%). The DLQI is the main QoL assessment tool used in forming the 
British Association of Dermatologists (BAD) guidelines (63, 64) and the National Institute for 
Health and Care Excellence (NICE) guidance (65). It is also widely recommended in 
Amercian and European guidelines (66, 67).  
 
The DLQI questionnaire aims to measure the impact of skin disease on various aspects of 
the respondant’s life over last 7 days, primarily to measure the current disease impact and to 
minimise the risk of recall bias. This can be considered as a limitation as a ‘snapshot’ view 
does not necessarily reflect on the overall impact of the disease. On the other hand, taking 
repeated measures and comparing scores between two time points (e.g. before and after 
treatment) can be helpful to evaluate the trend of changes. 
 
There was a concept that psoriasis affecting < 2% BSA is mild; 3%-10% is moderate; > 10 is 
severe. However, this concept was challanged and later omitted as studies have shown that 
BSA involvement does not correlate to the impact on quality of life (68-70). For instance 
those with genital or facial psoriasis can suffer major QoL impairment despite limited 
disease. Therefore, the three assessment tools (BSA, PASI and DLQI) should used together 
to evaluate disease severity. The ‘Rule of Tens’ was then introduced to describe severe 
psoriasis as BSA >10; PASI >10 or DLQI >10 (71). These three parameters are now 
implemented is several quidelines and commonly used in clinical trials and routine clinical 
practice.  
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Disease implications: 
 
Impact on Quality of Life: 
 
Psoriasis is a stigmatising condition. It can have a major impact on quality of life, equivalent 
to conditions such as cancer, heart disease, and diabetes (72). Møller et al (61) conducted a 
systematic review to compare QoL impairment caused by psoriasis to other chronic disease 
using the EuroQoL five dimension (EQ-5D) tool. In this review 12 studies met the inclusion 
criteria. The mean EQ-5D index scores for psoriasis ranged from 0.52 (standard deviation 
(SD = 0.39)) to 0.9 (SD = 0.1), which were within the range of those reported for other 
diseases like type 2 diabetes (range from 0.2 to 0.88); liver disease (range from 0.66 to 
0.79); cancers (range from 0.33 to 0.93); cardiovascular disease (range from 0.24 to 0.9) 
and end-stage renal disease (range from 0.44 to 0.86).  
 
The impact of psoriasis on appearance and function can greatly affect occupational, 
psychological and social elements of life (73). The condition may profoundly restrict personal 
life choices (74). Psoriasis can be itchy and painful, and application of topical therapies is 
time consuming and may involve mess and odour. Systemic oral therapies may have 
adverse effects and usually require blood-test monitoring and regular hospital appointments 
(75). The impact of psoriasis extends beyond individuals as it may also detrimentally affect 
other members of the family (76). 
 
About two-thirds of patients have a chronic course of psoriasis that requires continuous 
control (77). A systematic review on health economic analyses of psoriasis management 
identified several relevant studies with heterogeneity in models so drawing conclusions was 
not possible (78). The included studies also failed to factor patients’ loss of productivity. 
Another important factor to take into account is psoriasis-associated comorbidities and 
adverse effects from interventions.  
 
Psoriasis associated comorbidities: 
 
Optimising the psoriasis care pathway aims to place the patient at the centre of the 
management plan. Comorbidities associated with psoriasis should be recognised and 
managed appropriately in a timely fashion to avoid long-term complications. Psoriatic 
arthropathy is one example where early intervention is prudent to prevent irreversible joint 
damage. Screening for psoriatic arthritis (PsA) in all patients with psoriasis has been 
recommended by the Primary Care Dermatology Society (PCDS) and also highlighted in the 
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British Association of Dermatologists (BAD) guidance (64, 79). The prevalence of PsA has 
been reported variably in the literature, ranging from 6% to 42% (13). This variation could be 
due to various definitions used for PsA and whether point or period prevalence was 
measured.  
There is growing evidence that psoriasis is not solely a skin disease but rather a systemic 
inflammatory condition. Large population-based cohort studies in the UK demonstrated that 
severe psoriasis was an independent risk factor for myocardial infarction and cardiovascular 
mortality (80, 81). Moreover, emerging data shows an association between psoriasis and 
kidney disease, inflammatory bowel disease, infections, certain malignancies and mood 
disorders (13). Metabolic syndrome, defined as the combination of central obesity, 
hypertension, insulin resistance and dyslipidaemia (82), is an entity that has attracted 
interest in psoriasis research. A meta-analysis from a systematic review has shown that 
patients with psoriasis have more than double the risk of associated metabolic syndrome 
compared to the general population (OR 2.26 (95% CI 1.70 to 3.01)) (83). Although the 
exact pathogenesis is not fully understood, shared inflammatory pathways, genetic 
susceptability and common risk factors are hypothesised contributing factors. Moreover, it is 
controversial whether these comorbidites are secondary sequelae to psoriasis rather than a 
primary cause. 
 
Cardiovascular disease (CVD) risk factors (e.g. obesity, diabetes and hyperlipidaemia) were 
observed in those with psoriasis over three decades ago and it was believed that, while PsA 
was independent CVD risk factor, psoriatic skin disease was not (84). In a Dutch study by 
Dowlatshahi et al (85), 262 patients with psoriasis and 8,009 controls were followed up for 
11 years and there was no increased risk of CVD in psoriasis (adjusted hazard ration 0.73; 
95%CI 0.50 to 1.06). It was noted however that psoriasis patients were more likely to smoke 
and had higher diastolic blood pressure and BMI than those without psoriasis. This study 
involved mostly patients with mild psoriasis and so the results cannot be generalised to the 
whole psoriasis population. A pivotal study by Gelfand and co-workers using UK data (81) 
convincingly linked severe psoriasis as an independent risk factor with myocardial infarction, 
particularly in young patients. This was a large cohort study based on data collected from the 
General Practice Research Database (GPRD) between 1987 and 2002, comparing nearly 
127,000 patients with mild psoriasis and 3,837 patients with severe psoriasis to over 
500,000 controls, with adjustment for variables such as hypertension, diabetes, 
hyperlipdaemia, smoking, age, sex and BMI. The adjusted relative risk (RR) for myocardial 
infarction in a 30-year old patient with mild psoriasis was 1.29 (95%CI 1.14 to 1.46) and 3.10 
(95% CI 1.98 to 4.86) for the same age patient with severe psoriasis.  
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Another UK-based cohort study (86), also based on data from the GPRD, included 44,164 
patients with psoriasis and 219,784 matching controls, showed higher hazard ratio (HR) for 
several comorbidities in psoriasis than in matching control. These include diabetes (HR 1.33; 
95%CI 1.25 to 1.42); hypertension (HR 1.09; 95% CI 1.05-1.14), obesity (HR 1.18; 95% CI 
1.14-1.23) and hyperlipidaemia (HR 1.17; 95% CI 1.11 to 1.23); myocardial infarction (HR 
1.21; 95% CI 1.10 to 1.32), angina (HR 1.20; 95% CI 1.12 to 1.29), atherosclerosis (HR 
1.28; 95% CI 1.10 to 1.48), peripheral vascular disease (HR 1.29; 95% CI 1.13 to 1.47) and 
stroke (HR 1.12; 95% CI 1.00 to 1.25). Increased inflammatory markers such as C-reactive 
protein, leptin, osteopontin and other noted in psoriasis seem to play a role in both disease 
and comorbidities development (87). Moreover, a recent observational study (88) has 
highlighted the detrimental effect of psoriasis duration on vascular inflammation and major 
adverse cardiovascular events (Figure 8). The risk appeared to be greatest in those who 
had psoriasis for ≥ 10 years (n=29,220) followed by patients with psoriasis for < 10 years 
(n=57,941) in comparison to general population (n=4,234,793).  
 
 
Figure 8: Nelson-Aalen cumulative hazards graph of the population cohort showing major 
adverse cardiovascular event risk in patients with psoriasis stratified on the basis of disease 
duration (from Egeberg et al, 2017 (88)). 
 
The importance of recognising and treating these psoriasis-related comorbidities is 
highlighted in data reported from registries that patients treated with TNF-a inhibitors have 
reduced risks of CVD (89). This is an additional benefit of systemic therapy to patients which 
is used by the pharmaceutical industry to market new expensive drugs for psoriasis. 
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Although most of this data is derived from registries of rheumatoid arthritis patients, a recent 
retrospective cohort study showed a significant reduction of myocardial infarction in patients 
with psoriasis treated with TNF-a antagonists (HR 0.26; 95%CI 0.12 to 0.56) (90). 
Theoretically, supressing the inflammatory mediators with active treatments is likely to be 
responsible for this reduction. However, there has to be other important inflammatory 
pathways in the development of CVD other than TNF-a, and one question that remains to be 
answered is whether conventional systemic therapies can provide the same benefits as 
TNF-a inhibitors. Long-term prospective cohort studies are ideal to answer this question and 
the British Association of Dermatologists Biologic Interventions Register (BADBIR) is an 
ideal model to study this outcome.  
 
These data collectively point towards the necessity of a holistic approach in the management 
and treatment of psoriasis patients, with the aim of preventing / treating comorbidities rather 
than simply aiming to clear the skin plaques. Early intervention to detect and manage 
comorbidities is prudent to minimise complications and improve the long-term outcome of 
patients. Therefore, clinicians in both primary and secondary care should be proactive in 
patient-education (e.g. advise on body weight reduction, smoking cessation, healthy diet) 
and aim to refer patients with moderate to severe disease in a timely fashion to be treated in 
secondary care with systemic treatment to reduce the overall inflammatory process, and 
subsequently the long-term sequelae.   
 
Therapeutic choices for moderate to severe psoriasis:  
 
Psoriasis is one of the chronic skin conditions that is evidenced to affect individuals 
functioning and psychosocial wellbeing (91). It has been extensively studied in the past few 
decades, yielding better understanding of the complexity of its pathogenesis and 
developments in its therapeutic interventions. Until recently, oral therapies were established 
as the most effective treatment for severe psoriasis cases. Since then several biological 
treatments have emerged to offer better disease control, although at a much higher drug 
cost on the health services. Nevertheless, surveys from different countries showed that a 
large proportion of psoriasis patients are under-treated and remain on ineffective treatments 
for a long duration (92). 
 
Although psoriasis is incurable, there are several treatment options to achieve better disease 
control and improve patients’ quality of life (QoL). In the early days of Hippocrates, tar and 
topical arsenic were the treatments of choice for psoriasis. However, due to the lack of 
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knowledge combined with superstitious beliefs, traditional remedies have been used ranging 
from cat dung, goose semen, urine-onion-sea salt mix to the more toxic mercury, nitrate and 
sulphur containing applications (93). With the advancements in clinical and basic-science 
research, more treatments options have been developed. These range from topical 
therapies to phototherapy and systemic therapies (Figure 9).  
 
 
Figure 9: Range of therapeutic options in psoriasis in relation to disease severity. IL: 
interleukin; NB-UVB: narrow-band ultraviolet B; PUVA: psoralen and ultraviolet A; TNF: tumour 
necrosis factor. 
 
Most patients with milder psoriasis can be managed with topical therapies in the community. 
However, 25%-30% of patients have moderate-to-severe disease that requires secondary 
care intervention (94). Phototherapy is a recognised treatment option for psoriasis and it can 
be offered to patients with psoriasis that cannot be controlled with topical treatment alone 
(95). However, regular hospital visits (2-3 times weekly) for several weeks can be 
inconvenient. For example, patients may live far or are unable to take regular time off work. 
Some patients may also be excluded due to frail status or having contraindications to 
phototherapy. Moreover, duration of remission after phototherapy is variable and it is often 
not a solution for long-term control. Systemic therapies on the other hand may provide 
enhanced long-term control and, apart from monitoring appointments, patients are not 
required to attend frequent hospital visits.  
 
Systemic therapies for psoriasis: 
 
There are a number of systemic therapies for psoriasis and the choice of treatment needs to 
be decided on a case-by-case basis. Several factors play part in the decision-making 
process, including individual factors (psoriasis severity, age, comorbidities, personal 
preferences) and organisational factors (guidelines, clinicians experience, resources, funding 
and facilities). For a consent to be valid, it must be voluntary and informed, and the person 
consenting must have the capacity to make the decision (96). Being informed implies that 
patients must be provided with all the information needed to make a decision, including what 
the treatment involves, benefits and risks, and reasonable alternative treatments. The 
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information provided to patients about intended benefits and potential risks must be based 
on evidence so they can be as informed as possible. Although Patient Information Leaflets 
(PILs) about individual treatments are accessible via the BAD website and commonly 
provided to patients in clinics, making a decision can be an overwhelming and confusing 
process for patients. A treatment grid summarising and comparing therapies side by side 
can be a valuable aid. The National Psoriasis Foundation (NPF) has put forward a similar 
chart (97). The BAD provides PILs on treatments for moderate or severe psoriasis (98) but 
does not provide head-to-head comparisons of possible adverse effects and other factors 
influencing choice of treatment.  
Methotrexate (MTX) was approved in 1958 as the first systemic therapy for psoriasis (99). 
This was around the same time fumaric acid esters (FAE) were discovered as a treatment 
option for psoriasis (100). However, FAE did not have the approval in Germany until 1994, 
around the same time retinoids and ciclosporin were licensed, in 1992 and 1993 respectively 
(99). The vast development in understanding psoriasis pathogenesis in the past two 
decades has led to the development of more effective targeted therapies, such as biologics. 
Since the approval of the first biologic interventions for psoriasis 14 years ago, several 
others have emerged. These have shown greater efficacy in clearing psoriasis than 
conventional systemic therapies. However, in the current era of evidence-based medicine 
and economic pressure, effective, safe and affordable treatments are prioritised.  
 
Methotrexate: 
Methotrexate (MTX) is the most commonly used systemic treatment for moderate to severe 
plaque psoriasis, especially in cases with joint involvement (101). It competitively inhibits the 
enzyme dihydrofolate reductase and other folate-dependent enzymes. Inhibition of nucleic 
acid synthesis in activated T cells and keratinocytes resulting in the immunomodulatory and 
antiproliferative effects, respectively, are believed to be the main therapeutic effect of MTX in 
the treatment of psoriasis (99). It is administered once weekly orally or subcutaneously. The 
initial dose should be 5 to 10mg followed by gradual dose increments, up to 30mg a week, 
depending on response and tolerance (99). The addition of folic acid has been shown to 
reduce MTX-associated gastrointestinal adverse effects and hepatic dysfunction (102). 
 
A recent study by West et al (103) reported the long-term efficacy and tolerability of MTX 
under real-word conditions. The study included 333 psoriasis patients treated with MTX for a 
median duration of 33 months. It was noted that the majority of treatment failures occurred 
during the first year of treatment and patients were likely to remain on treatment long term 
beyond this point. Interestingly, the most frequent reason for treatment discontinuation was 
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adverse effects rather than lack of efficacy; the latter was reported in approximately 10% of 
patients.  
 
Ciclosporin: 
Ciclosporin exerts a rapid immunosuppressive effect and so can be used in cases where 
quick response is desired. It acts by inhibition of CD4+ T cells, which leads to reduced 
synthesis of interleukin-2 and prevents T cell proliferation (104). The standard dose is 2.5 to 
3mg/kg/day which can be increased slightly if needed and monitoring parameters are 
satisfactory (99). Nephrotoxicity is a major drawback of this treatment, which increases with 
higher doses (e.g. 5mg/kg/day) (105). Therefore, it is used as a short-term intervention. 
Another major limitation of long-term use of ciclosporin is its carcinogenic effect. In a five-
year prospective cohort study by Paul and colleagues (106) including 1252 psoriasis patients 
treated with ciclosporin, the incidence of skin cancer, mostly squamous cell carcinoma, was 
six-fold higher in the treated group compared with the general population. This risk was 
greater in those who received the treatment for more than two years. However, the incidence 
of non-skin malignancy was not significantly different. 
 
Acitretin: 
Acitretin, a vitamin A analogue, is another systemic therapy used in psoriasis. It has the 
advantage of non-immunosuppressive effects. Retinoids bind to nuclear receptors from the 
steroid hormone receptors family (107), resulting in antiproliferative and immunomodulatory 
effects. They reduce the proliferation and regulate the differentitation of epidermal 
keratinocytes, reduce intraepidermal migration of neutrophils and inhibit IL-6-driven induction 
of Th17 cells. The dose ranges from 0.3 to 0.8 mg/kg/day, adjusted based on response and 
tolerance (99). A higher dose of acitretin is more effective but xerosis and chilitis are more 
encountered. Three RCTs from the 1980s ((108-110) demonstrated that acitretin 50–75 mg 
daily was significantly better than placebo and a lower acitretin dose (10–25 mg daily) in 
treating psoriasis, but no PASI scores were reported and the dropout rate due to adverse 
effects was unclear. As a teratogenic agent, it is usually avoided in females of childbearing 
age, as contraception for three years following treatment discontinuation is necessary (107). 
 
Apremilast: 
The phosphodiesterase 4 inhibitor, apremilast, is a small molecule drug which gained NICE 
approval for the treatment of moderate to severe plaque psoriasis in adults in 2016 (111). It 
reduces the production of proinflammatory TNFa and IFNg in psoriasis. The dose is 
administered orally at 30mg twice daily (112). In the ESTEEM 1 study published by Papp et 
al (113), 75% reduction in PASI score (PASI75) was achieved in 33.1% of those received 
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Apremilast (n=562) 30mg twice daily for 16 weeks, compared to 5.3% of those received 
placebo (n=282) (P <0.0001). However, the majority of Apremilast-treated patients 
experienced diarrhoea (72.4%) and nausea (77.4%) within two weeks after first dose. A 
warning was issued by the Medicines and Healthcare products Regulatory Agency a year 
after Apremilast NICE approval to highlight increased risk of psychiatric symptoms with the 
medication, including depression, suicidal thoughts and suicidal behaviours(114).  
 
Fumaric acid esters: 
Although FAE are licensed and widely used in Germany for the treatment of psoriasis since 
1994, it was evident from the literature that they have also been used, as an off-label drug, in 
other countries such as the Netherlands (115-117), the United Kingdom (118, 119) and Italy 
(120, 121). Studies have shown that dimethyl fumarate (DMF) is the active ingredient of FAE 
(see Chapter 3). In September 2017 (after the publication of our Cochrane systematic 
review), a DMF alone preparation has gained the European Medicines Agency (EMA) (122) 
and National Institute for Health and Care Excellence (NICE) (123) approval for the 
treatment of moderate-to-severe psoriasis.  
 
The treatment regimen starts with DMF 30mg tablets once daily, increased gradually to three 
times daily in the first 3 weeks of treatment then followed by DMF 120mg tablets once daily 
from week 4 to a maximum of six tablets daily (720mg) in week 9. This gradual dose 
increments has been proposed to improve tolerability, mainly gastrointestinal adverse 
effects. Lymphopaenia is a recognised potential side effect of DMF and hence blood 
monitoring, and treatment discontinuation if necessary, are essential safety measures.  
 
Aims of this thesis: 
 
The psoriasis care pathway has been summarised in NICE guidelines (Figure 10) and 
includes primary care management, referral to secondary care when required, and selection 
of appropriate phototherapy, systemic and biologic therapies in secondary care (124). The 
objective of this research project is to generate data relevant to clinical practice to improve 
the care psoriasis patients receive through their journey in the healthcare system. 
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Figure 10: An overview of psoriasis care pathway (from NICE pathways (124)).  
 
Access to care ‘In the right place, at the right time, by the right people’ has been prioritised 
by the Welsh Assembly Government in their 2005 policy ‘Designed for Life: Creating world 
class health and social care for Wales in the 21st century’ (125). As psoriasis is a life-long 
condition with intermittent remissions and flares, and causes a significant impairment of 
patients’ quality of life, patients’ care should be more streamlined to be enable those with 
significant disease to be seen by a specialist in secondary care at the right time. This 
stimulated our thoughts to perform the first of the two projects that comprise this thesis to 
address the issue of timely referral from primary care.  
 
When patients with moderate-to-severe psoriasis are seen in secondary care, systemic 
therapies are often considered to achieve long-term disease control. The choice of the 
systemic therapy can be influenced by different factors, as previously discussed. At the time 
of starting the MD project, FAE were unlicensed for psoriasis in the UK. As a result, FAE 
were omitted from guidelines and standard sources of patient information, leaving clinicians 
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and patients unsupported in considering FAE treatment. This is particularly important in the 
context that, as an unlicensed intervention, clincians were more exposed medicolegally in 
prescribing FAE. As a result, there was considerable variation in FAE prescribing for 
psoriasis across the UK, depending on individual clinicians’ familiarity with the intervention. 
Thus, there was a need to provide a robust evidence on the use of FAE for psoriasis. The 
project involved conducting a Cochrane systematic review of FAE for psoriasis because the 
Cochrane Collaboration provides a framework to conduct the highest quality systematic 
review that is most accessible to patients as well.  
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CHAPTER 2 
Optimising psoriasis referrals from primary care: Dermatology 
Life Quality Index (DLQI) as a triage tool  
 
 
There is substantial evidence indicating that psoriasis patients are under-treated. A German 
survey including 1511 psoriasis follow-up patients in dermatology clinics revealed an 
average PASI score of 12 and DLQI score of 8.6, indicating moderate-to-severe disease, 
and only 45.4% of those with PASI > 20 had been prescribed systemic therapies (126). 
However, the cross-sectional study design does not provide the clinical outcomes for these 
patients. Further surveys from the US National Psoriasis Foundation (127), including 1657 
patients, and Canada (128, 129) showed 37% and 18% of patients, respectively, received 
systemic and/or phototherapy. The Canadian surveys found that only 24% of participants 
were satisfied with their treatment at the time of the survey and demonstrated patients’ lack 
of awareness of available treatment options.  
 
There are several possible reasons to explain insufficient treatment of psoriasis patients. 
Potential reasons include lack of local resources, insufficient patient education regarding 
available therapies or concerns about treatment-related adverse effects, lack of access to 
specialist care or reluctance from clinicians to initiate therapies that require long-term visits 
and monitoring in the current era of meeting targets. Another possible explanation of under-
treatment is the lack of utilising quality of life measures that play a central role in treatment 
goal and management plan. Although assessment of psoriasis impact on patients’ 
psychosocial wellbeing is part of NICE Clinical Knowledge Summaries (NICE-CKS) 
guidance (130), guidance from the Primary Care Dermatology Society (PCDS) (79) lacks a 
recommendations regarding QoL measurement in psoriasis. Correction of this omission may 
help encourage QoL measurement by GPs to assist their management of psoriasis. 
 
Currently, almost all written primary care psoriasis referrals are triaged as ‘Routine’. In part 
this is because of the prioritisation of skin cancer. The length of routine waiting times when 
this study was carried out was 9-10 months; this means that many patients with severe 
psoriasis wait several months to be seen, enduring a preventable reduction in quality of life. 
Furthermore, due to the relapsing/remitting nature of psoriasis, some patients have 
spontaneously recovered from their psoriasis flare by the time they are reviewed by a 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 21 
specialist and so the appointment is unnecessary at that time. This results in a frustrating 
situation for patients, GPs and dermatologists.  
It is challenging for GPs to undertake a physical signs based measure of psoriasis severity 
with limited training and insufficient consulting time to fully expose a patient. In the context 
that quality of life scores are now used by NICE and other guideline producers, the 
hypothesis of the project is that patient self-assessed QoL may be an efficient and helpful 
tool to allow GPs to select those psoriasis patients requiring referral to secondary care. It 
may also support effective triage of the referrals by secondary care. 
 
Dermatology Life Quality Index (DLQI) is the most validated and widely used dermatology-
specific quality of life measure in current use (62, 131). It is self-completed by patients in 1-2 
minutes (59). The questionnaire includes 10 items, answered by selecting relevant level of 
impact (very much, a lot, a little, not at all), yielding a total score ranging from zero to 30 
(Appendix 1). A DLQI cut-off score of greater than 10 indicates a very large effect on a 
patient’s quality of life, whereas scores of 10 or less reflect a moderate or small effect (59, 
132). It can be completed by the patient before or after the GP consultation, to ensure that 
consultation duration is unaffected.  
 
A previous longitudinal study by Basra et al (133) demonstrated that a 4-point difference in 
DLQI scores represents minimal clinically important difference (MCID). The MCID has been 
defined as ”the smallest difference in score in the domain of interest which patients perceive 
as beneficial and which would mandate, in the absence of troublesome side effects and 
excessive costs, a change in the patient’s management” (134).  
In order to optimise the care provided to psoriasis patients the present study has been 
proposed to evaluate the usefulness of the DLQI questionnaire in triaging patients referred to 
dermatology secondary health care services.  
 
Study Aims: 
- Primary aim: to assess whether DLQI questionnaire can be a useful triage tool when 
patients with psoriasis are referred from primary to secondary health care.  
- Secondary aims: 
o To assess the average DLQI score in newly-referred psoriasis patients. 
o To determine the difference between DLQI scores at GP referral and on 
review by a specialist. 
o To investigate the degree of patient satisfaction with the referral waiting time. 
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o To assess the correlation between PASI and DLQI scores when patients are 
seen in secondary care. 
o To assess the effect of psoriasis duration on DLQI scores. 
Study Design: 
 
A single-site questionnaire-based controlled study on newly-referred patients with psoriasis 
to the department of dermatology at University Hospital of Wales (UHW).  
 
Methods: 
 
Local GPs were provided with DLQI questionnaires to use when referring patients with 
psoriasis. The Principal Investigator (PI) screened all referral letters received from GPs with 
a stated diagnosis of psoriasis. DLQI questionnaires were sent to the referring GPs 
requesting these to be filled in by referred patients. Completed forms then were returned to 
the PI via the GP. This ensures the communication occured between the PI and referring 
GPs only.  
 
In agreement with the Cardiff consultant dermatologists based at the University Hospital of 
Wales (UHW), the PI triaged referred patients with a DLQI score greater than 10 as ‘Urgent’ 
(10-12 weeks wait) while those with no DLQI scores, either from participating or non-
participating GPs, were triaged as ‘Routine’ (9-10 months wait) as a control group (Figure 
11). This produced two groups for comparison: 1- a group with DLQI score more than 10, 
and a group with no DLQI score. 
 
 
Figure 11: Outline of the study flowchart.  
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In the first version of the protocol, a third group with DLQI scores of 10 or lower was planned 
to be included. However, a protocol amendement was submitted to exclude this group from 
the study as no referrals had been made for these patients. It is assumed that they were 
managed in primary care as their psoriasis had no major impact on their quality of life.  
 
Referred patients received the study information sheet (Appendix 2) when they arrived for 
their first appointment at the dermatology department. Patients had time to read the 
information in the waiting area before they were invited to take part by the study PI. Potential 
participants were either recruited on the day or allowed up to two days to decide whether 
they wished to take part. Patients were allowed to ask any questions related to the study 
before they were requested to sign a written informed consent (Appendix 3). If they preferred 
not to take part, their data were not included in the study and they were reviewed in the clinic 
in the usual way. If they agreed to participate, the researcher invited the patient for a 20-30 
minute consultation. The researcher recorded on a data collection sheet (Appendix 4) 
demographic information, current and previous psoriasis treatment, co-morbidities, DLQI 
scores (currently and at the point of referral if applicable), the waiting time from the GP 
referral to their secondary care appointment and patient satisfaction with the waiting time on 
a five-point Likert scale. PASI score (Appendix 5) was also measured. Participants then saw 
the Consultant’s outpatient team in the usual way, who had access to the collected data to 
aid the consultation.  
 
Study Population: 
Patients with psoriasis referred from primary care to the department of dermatology at the 
UHW (study site) were recruited. 
 
Inclusion Criteria: 
§ New referrals with a clinical diagnosis of psoriasis, confirmed by a dermatologist 
§ Adults aged at least 18 years 
§ Able to understand and write English 
§ Able to give informed written consent 
 
Exclusion Criteria: 
§ Patients unable or unwilling to sign the consent form. 
 
Sample Size: 
A power calculation demonstrated that 20 patients were required in each group to give 80% 
power to detect a five point difference in PASI score for an alpha significance level of 0.05.  
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Number of Visits: 
Participants were assessed once for around 20 minutes prior to the first consultation with the 
specialists. No further visits were required for the sake of the study but those who required 
follow-up for their psoriasis management were reviewed in clinics as needed.  
 
Data Recording and Retention of Documents: 
Research data were entered onto data collection sheets (Appendix 4). All the research 
documents were kept securely in the Department of Dermatology of UHW. Only the study 
investigators could access these data. 
 
Study Outcomes and Data Analysis: 
The primary outcome for the study was the PASI score at the time of outpatient review in the 
two groups: DLQI score greater than 10 and no DLQI score in referral letter. Patient 
satisfaction with the waiting time was also measured on a five-point Likert scale. The data 
generated from the study was reported using descriptive statistics. 
 
Ethical and Legal Consideration:  
Ethical Approval from the South East Wales Local Research Ethics Committee (Appendix 6) 
was obtained on 19 July 2012 (REC reference: 12/WA/0212). Amendments were submitted 
to the committee and no changes were made to the conduct of the study until approval was 
granted. 
 
All participants were required to give their written consent after the nature of the study had 
been fully explained. The researcher informed the GPs if their referred patients participated 
in the study. All original consent forms and study data were kept in a secure location. Three 
consent forms were signed, one for the subject, one for the patient notes and one to be 
stored securely in the Trials Unit, Department of Dermatology at UHW. The participants were 
informed that they could withdraw their consent at any stage without being required to state 
a reason and without prejudice to any future care. Study documentation was available for 
examination by regulatory authorities for monitoring the quality of the research during the 
course of the study. The data could be identified only by the date of birth and a unique study 
number.  
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Funding:  
Funding was approved by the Dermatology Forum for Wales (Appendix 7). This was utilised 
to fund staff time. 
Sponsorship: 
This study was sponsored by Cardiff University (Appendix 8). 
 
Project Management: 
Dr John Ingram supervised and monitored the project. The Trial Management Group (Dr 
John R Ingram and Dr Ausama Abou Atwan) met frequently to discuss the study progress 
and to ensure adherence to study protocol. A Clinical Trials Nurse helped in printing and 
posting DLQI forms to referring GPs, and in storing the study documents.  
 
Results: 
The 40 recruited patients, 20 in each group, had no significant difference in demographics 
and disease characteristics (Table 1). The median waiting time for the ‘urgent’ group was 88 
days (interquartile range (IQR) 66-99 days) whereas patients triaged as ‘routine’ waited 256 
days (IQR 228–295 days).  
 Routine (no DLQI at referral) Urgent (DLQI > 10 at referral) 
Number  20 20 
Gender  M=9; F=11 M=11; F=9 
Age median (years) (IQR) 34 (28-51) 40 (33–52) 
Psoriasis duration median (years) (IQR) 13 (8.5-20) 8.5 (4-20) 
Body Mass Index (BMI) (median kg/m2) 
(IQR) 
27.1 (23.4–31.2) 29.2 (26–33.5) 
Family history of psoriasis  10 9 
Co-morbidities 11 (HT=5; 
hypercholesterolaemia=2; 
depression=8) 
8 (HT=4; DM=1; 
hypercholesterolaemia=2; 
depression=2; PsA=2) 
Waiting time median (days) (IQR) 256 days (228–295) 88 days (66–99) 
Table 1: Participants’ characteristics. HT: hypertension; IQR: interquartile range; PsA: Psoriatic 
arthritis.  
 
Of those patients seen urgently, 60% were ‘happy’ or ‘very happy’ with the waiting time. In 
contrast, in the routine group no patients were ‘happy’ or ‘very happy’. The median PASI 
score in the urgent group was 6.2 (IQR 3.5–10.6) compared to 3.85 (IQR 2.8–6.3) in the 
routine group (P = 0.0968) (Figure 12).  
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Figure 12: The median PASI scores in the urgent and routine groups.  
 
The median DLQI score in the urgent group when seen in secondary care was four points 
higher compared to the routine group (urgent=16, IQR 12-20, vs. routine=12, IQR 8.5–17) (P 
= 0.097) (Figure 13), reflecting higher disease impact as shown by the difference reaching 
the level of the MCID for the DLQI instrument (133). In those triaged as urgent, the median 
DLQI score at the time of secondary care assessment was not significantly different 
compared to their baseline scores at the time of referral (17.5; IQR 13.5–23) (P = 0.15625)  
 
 
Figure 13: The median DLQI scores in the urgent and routine groups. 
 
Pearson correlation coefficient calculation showed no significant correlation between PASI 
and DLQI scores in both urgent (R=0.3207) and routine (R= 0.3809) groups. Similarly, no 
significant correlation was noted between the duration of participants’ psoriasis and their 
DLQI scores when presented in secondary care (R= - 0.1921).  
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 27 
Discussion:  
Pressures on dermatology secondary care services in the UK and a requirement to meet 
skin cancer waiting time targets results in patients with inflammatory dermatoses having long 
waiting times. Triaging GP referrals accurately is difficult if information is incomplete and 
disease severity scores are not given. Asking GPs to perform a severity score involving 
complete skin examination, such as PASI, is not practical because of lack of time and 
insufficient training. However, a QoL questionnaire can easily be completed by patients while 
the GP documents the consultation. Patients seen urgently due to a baseline DLQI score > 
10 at referral had a DLQI score four points higher than those referred without a DLQI and 
seen ‘routinely’. As the minimal clinically important difference (MCID) for DLQI is four points 
(133), using a baseline DLQI score greater than 10 does identify those patients whose 
psoriasis has a particularly high impact on QoL, compared to an unselected group of 
psoriasis referrals. 
 
Cardiff’s long waiting time of 256 days for routine referrals reflects pressures on dermatology 
secondary care services in Wales. While we chose a DLQI cut off score of 10 points, as it 
indicates major impairment of QoL, a different cut off score could be selected depending on 
the attitude and resources of the referral centre. The Scottish (135) and Malaysian (136) 
guidelines recommend referral for DLQI scores >5 in psoriasis patients unresponsive to 
topical therapy. However, in keeping with our study experience, 65.5% of eligible patients in 
Scotland were not seen by a specialist (137). 
 
This study, although small in size, demonstrated the associations with comorbidities in line 
with reports in the literature. Obesity, defined by the World Health Organisation (WHO) as 
Body Mass Index (BMI) of 30 or greater (138), was the most common association, noted in 
17 (42.5%) of our cohort. This was followed by depression (n=10; 25%), hypertension (n=9; 
22.5%), and dylipidaemia (n=4; 10%). Therefore, a holistic management approach is prudent 
in psoriasis patients to improve their overall health status, not just the visible skin disease.  
 
One limitation of the study is the lack of a separate group of psoriasis referrals with a DLQI 
score ≤10. Although this was initially planned in the first version of the study protocol, we 
found that almost no patients were referred with scores in this range, perhaps because GPs 
chose not to refer less severely affected patients. Another potential limitation is the 
possibility that patients or GPs might inflate DLQI scores to reduce waiting time delays, 
however we mitigated for this in our study by not specifying the DLQI score triage cut-off for 
urgent appointments.  
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The course of psoriasis severity can fluctuate unpredictably. When patients are referred 
routinely from their GP their psoriasis can be milder by the time they see the specialist 
several months later. As a result, the outcome may be advice on topical therapies and 
discharge from further follow up. This common clinical scenario can be frustrating to patients 
who need to see the GP to be referred again when their condition flares and wait more 
months to be seen again in secondary care. To break this vicious circle, and to implement 
the NICE guidance which indicates that patients with psoriasis should have a single point of 
contact to access information or advice (95), a more responsive healthcare model is needed.  
 
Such a model was established by the department of dermatology at the Aneurin Bevan 
University Health Board in 2013 and given the name “Psoriasis Direct Service” (139). This 
was specifically designed for psoriasis patients seen in secondary care and not requiring 
phototherapy, systemic treatment or regular monitoring. The aim was to empower these 
patients to self-refer when needing advice and/or review by a Clinical Nurse Specialist 
(CNS), who in turn triaged patients according to their needs. This ‘open-access’ model has 
no time cut-offs after the initial clinic consultation. This service was audited two years after 
its launch (139). It was found that 645 psoriasis patients were provided with written 
information on the service, including the phone number of the CNSs. Of those, 203 patients 
(31.5%) contacted the service of whom 166 (81.8%) were then reviewed in person by the 
CNS after an average period of 27 days (range 0 to 148 days). This represents a timely 
review as opposed to the routine outpatient waiting time if re-referred to secondary care by 
the GP. The mean time for contacting the service after the initial clinic consultation was 7.2 
months (range 0 to 34 months). This means a fixed three- or six-month follow-up 
appointment would have been unnecessary for these patients and the appointment slots 
were used more effectively. Importantly, the majority of patients (91%) rated this service as 
good/excellent. These findings suggest that several models, including DLQI measurement, 
can streamline referrals, free up appointments and improve patient care at the interface 
between primary and secondary services. The positive rating from patients indicates their 
satisfaction and reassurance from having access to a specialist service when needed.  
 
In summary, we have demonstrated that a QoL instrument such as the DLQI can be used as 
a triage tool. Its use may help GPs quantify psoriasis severity, and ensure that patients 
whose psoriasis is causing greatest impact on QoL are prioritised for referral and seen in 
secondary care in a timely manner. A much larger randomised study is needed to evaluate 
the usefulness of DLQI as a triage tool in dermatology services. 
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Dissemination of Study Findings: 
The study was published as a research letter in the British Journal of Dermatology (140) 
(Appendix 9). 
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CHAPTER 3  
Fumaric acid esters in the treatment of psoriasis: A Cochrane 
Systematic Review 
 
 
Historical Background:  
 
Fumaric acid esters (FAE) are chemical compounds derived from fumaric acid (FA); they 
have a combination of methyl and ethyl groups added to fumaric acid backbone (141). 
Schweckendiek, a German chemist who had psoriasis, proposed that psoriasis develops 
due to disturance in the citric acid cycle where fumaric acid (FA) was lacking. Because of the 
poor oral absorption of FA and its high irritancy (e.g. induction of gastric ulceration), 
Schweckendiek esterified it into monoethyl fumarate (MEF), monomethyl fumarate (MMF), 
diethyl fumarate (DEF) and dimethyl fumarate (DMF) in enteric coated tablets which had 
increased efficacy and bioavailability (141-143). In 1959, he reported successful treatment of 
psoriasis with FAE after self- experimentation (100).   
 
Several combinations of the components were tried following Schweckendiek’s report until 
the treatment was standaridised by Schafer in 1982 (144). A couple of years later, it was 
known as Fumaric Acid Compound Therapy, or FACT (145). This consisted of DMF, 
mixtures of FA and several MEF salts (calcium, cupric, ferrous, potassium, lithium, 
magnesium, manganase and zinc) (146). This compound was used along with topical MEF 
1-3% ointment or bathing oil and strict diet (avoiving spices, etheric oils, nuts and wine) and 
so it was inconvenient (145). Therefore, a simplified version of the treatment was developed, 
consisting of low and high dose of DMF tablets including only three MEF salts (calcium (Ca), 
zinc (Zn) and magnesium (Mg)). This formula was then approved in Germany in 1994 and 
given the brand name Fumadermâ. The dietary restrictions were dropped because no added 
benefit was noted.  
 
Fumadermâ (Biogen Idec Inc) is available in two strengths (147): 
- Fumadermâ Initial, containing 30mg of DMF per tablet plus MEF-Ca 67mg, MEF-Zn 
3mg, and MEF-Mg 5mg 
- Fumadermâ, containing 120mg of DMF per tablet plus MEF-Ca 87mg, MEF-Zn 3mg, 
and MEF-Mg 5mg.  
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Dimethyl fumarate (DMF) is believed to be the active ingredient that exerts clinical effects in 
psoriasis. This was first elucidated by Nieboer et al in 1989 (146) in a publication of a series 
of five open-label and controlled studies. It was concluded that MEF monotherapy was not 
superior to placebo, assessed by a Psoriasis Severity Score (PSS), whereas DMF 240mg 
daily as monotherapy was superior to placebo and induced considerable improvement in 
22% of patients at 4 months and in 33% of patients at 9 months. This study also reported a 
statistically significant correlation between treatment-induced lymphopaenia, occurring in 
60% of those who received DMF, and considerable psoriasis improvement (≥ 50% 
improvement in PSS). This observation however was based on a small number of patients.  
 
A year later, the same study group conducted a double-blind, head-to-head trial to compare 
FAE compound therapy (DMF plus salts of MEF) with DMF monotherapy (148). In this study 
they demonstrated >50% improvement of PSS in 55% of those who received DMF (n=22) 
and 80% in the combined FAE group (n=23) but the difference was not statistically 
significant at the study endpoint at 4 months. Four patients (18%) in the DMF group 
discontinued treatment due to therapy-related adverse effects in comparison to 7 (30.4%) in 
the FAE mixure group; yet this difference was not reported whether statistically significant. 
As a result, the authors concluded that FAE mixure did not have additional therapeutic 
benefit over DMF monotherapy.  
 
A DMF monotherapy preparation manufactured in the Netherlands called Psorinovoâ (GMP 
Apotheek Mierlo-Hout) is available and used for psoriasis treatment for over 2 decades, 
although it is not registered through the Dutch Medicines Evaluation Board (149). In addition, 
a delayed-release oral formuation of DMF, Tecfideraâ (120mg and 240mg) (Biogen Idec Inc) 
is licensed for the treatement of relapsing-remitting multiple sclerosis. It was approved for 
this indication by the Food and Drug Administration (FDA) (150) and EMA (151).  
 
Tolerability: 
Gastrointestinal (GI) adverse effects are common with FAE but in the majority of patients 
they are mild in severity and ease with time. Severe symptoms however can lead to 
treatment discontinuation. A gradual dose-increment schedule of Fumadermâ is well 
established in the European S3 guidelines (99) (Table 2) and is meant to improve 
tolerability. The same dosing schedule is advised for the recently approved DMF-only 
product, Skilarenceâ.  
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 Table 2: Dosing schedule for FAE (from Pathirana et al (99)).  
 
One strategy to improve the tolerability of FAE is gradual dose increments on starting 
therapy according to the recommended dosing schedule (99). It is common in routine 
practice to be even more cautious with dose increments if patients still develop the common 
adverse effects of GI symptoms and flushing. Another strategy that was recommended in the 
Dutch guidelines (152) and in an expert panel recommendation for patients receiving DMF 
for multiple sclerosis (153) is prescribing antihistamines for those experiencing these 
adverse effects. This is based on the hypothesis that GI symptoms and flushing are similar 
to histamine-mediated symptoms (154). However, Balak et al (155) tested this theory by 
conducting a randomised placebo-controlled trial to assess if antihistamine addition to FAE 
would reduce the adverse effects. This trial included 50 participants with a median age of 44 
years and PASI score ≥ 10. All participants received the FAE according to the standard dose 
increment schedule for 12 weeks, and half of the participants were randomised to receive 
cetirizine 10mg once daily whereas the other half received additional placebo tablets. At the 
study end-point it was observed that the addition of cetirizine did not reduce the incidence of 
adverse effects compared with placebo (84% in each group, P = 1.00) and the proportion of 
participants who dropped out due adverse effects did not statistically differ (24% vs. 32%, P 
= 0.53). This study however included a relatively small sample size and so may have been 
under-powered to detect a difference. 
 
Pharmacokinetics: 
After oral intake, DMF is rapidly hydrolysed by esterases in the gut to monomethyl fumarate 
(MMF). This rapid conversion is believed to be the cause of lack of detectable DMF in the 
blood circulation (141, 156). There is growing evidence to show that MMF is the prinicple 
active molecule in vivo after FAE oral administration (157). MMF reaches peak plasma 
concentration after 3.5 – 5 hours where it is metablised via the citric acid cycle to fumaric 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 33 
acid, water (H2O) and carbon dioxide (CO2) (158). So, the majority of DMF metabolites 
(89%) are excreted by CO2 exhalation (141, 159). A small proportion (11%) may enter the 
systemic circulation where it forms cysteine and N-acetyl cysteine conjugates of mono- and 
dimethyl succinate, excreted in urine (160). As urinary excretion plays a minor role in DMF 
metabolism, dose adjustment is not usually required for patients with renal impairment (159).  
 
Mechanism of action: 
The mode of action of FAEs is complex and appear to be multi-faceted. The different 
mechanisms of actions have been recently reviewed by Brück et al (159) and are 
summarised below (Table 3). Yet, the full pharmacokinetic profiles of DMF and MMF remain 
unclear and to be elucidated.  
 
Author Mechanism of action Effect 
Ghoreschi et al (161)  
Lehmann et al (162)  
Dibbert et al (163)  
Rostami-Yazdi et al (164) 
Schmidt et al (165) 
Peterson et al (166) 
Schmidt & Dringen (167) 
Influencing intracellular 
glutathione levels via binding 
of DMF/MMF to thiol groups 
of glutathione 
 
Regulation of cellular 
responses to oxidative stress 
 
Wilms et al (168) 
Linker et al (169)  
Gold et al (170)  
Helwa et al (171) 
 
Activation of Nrf2 by 
DMF/MMF 
 
Regulation of cellular 
antioxidant responses and 
stimulation of cytoprotective 
and anti-inflammatory factors 
such as HO-1 
 
Ghoreschi et al (161) 
Vandermeeren et al (172)  
Loewe et al (173)  
Litjens et al (174) 
Mrowietz & Asadullah (160) 
Gerdes et al (175) 
Moharregh-Khiabani et al (176)  
Peng et al (177) 
 
Indirect and/or direct inhibition 
of NF-κB activity by DMF 
 
Influencing cytokine production 
by antigen-presenting cells, 
inhibition of Th1/Th17 
responses, promotion of Th2 
responses 
Ghoreschi et al (161) 
Zhao et al (178)  
Li et al (179)  
Kang et al (180) 
 
Modulation of oxidative 
stress-sensitive transcription 
factors HIF-1α and STATs by 
DMF 
 
Inhibition of genes regulated by 
HIF-1α and STAT3/STAT1 
 
Tang et al (181)  
Hanson et al (182, 183)  
Chen et al (184) 
 
Agonism of HCA2 by MMF  
 
Formation of COX-1 and 
PGE2, inhibition of neutrophil 
recruitment 
 
Table 3: Summary of the main mechanisms of action of DMF/MMF. DMF: dimetyl fumarate; 
HCA2: hydroxy-caroxylic acid receptor 2; HIF-1α: hypoxia-inducible factor 1-alpha; HO-1: 
hemeoxygenase 1; MMF: monomethyl fumarate; NF-κB: nuclear factor kappa-light-chain-enhancer of 
activated B cells; Nrf2: nuclear factor (erythroid-derived 2)-like 2; STAT: signal transducers and 
activators of transcription. (adapted from Brück et al (159)) 
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To date, at least five mechanisms for DMF/MMF have been described in the treatment of 
psoriasis (159).  
- After cellular uptake, the α, β unsaturated carboxylic acid easter DMF reacts with 
thiol groups of glutathione and lowers its levels. This as a result impacts cellular 
responses to oxidative stress  
- Activation of nuclear factor-like 2 (Nrf2) dependent antioxidant response pathway 
leads to stimulation of cytoprotective and anti-inflammatory genes 
- Inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
activity affects cytokine production and the phenotype of APCs, which shifts 
Th1/Th17 immune response to a Th2 phenotype, resulting in anti-inflammatory 
response 
- Inhibition of hydroxy-caroxylic acid receptor 2 (HCA2) which influences neutrophil 
adhesion, migration and recruitment, and 
- Modulation of oxidative stress-sensitive transcription factors such as hypoxia-
inducible factor 1-alpha (HIF-1α) and signal transducers and signal transducers and 
activators of transcription (STAT).  
 
Biological Effects in Psoriasis: 
 
Most of the data describing the actions of FAE are derived from in vitro studies. The 
complexity of FAE ingredients and pharmacokinetics also add to the challenge of 
understanding the biological effects they exert in psoriasis. However, data indicate multiple 
effects of fumarates on different cell types relevant to psoriasis pathogenesis as summarised 
below.  
 
LYMPHOCYTES: 
It has been shown that resident T lymphocytes, macrophages and neutrophils infiltrate 
psoriatic lesions before the development of significant epidermal changes (185, 186). T 
lymphocytes play a role in the development of psoriasis in three stages: activation, migration 
into the skin and release of cytokines (187). FAE interfer in this process, through the 
inhibition of NF-kB, by inducing immune cells apoptosis and preventing the release of 
inflammatory cytokines. In vitro studies have indeed demostrated the potent apoptotic effect 
of DMF (188) and their ability to impair the release of T-cell cytokines (189). A study in six 
patients treated with DMF for 16 weeks showed a significant reduction of lesional T-cell 
subset and normalised epidermal proliferation (190).  
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KERATINOCYTES:  
Dimethyl fumarate has been shown to strongly suppress chemokine expression by 
keratinocytes (191) and inhibit keratonocyte cell proliferation and differentiation in vitro in a 
dose-dependent manner (188). The anti-proliferative effect of DMF and MMF is believed to 
occur as a result of transient increase of intracellular calcium in human keratinocytes (192). 
Another in vitro study using human keratinocyte cell line showed that DMF could also 
downregulate the expression of cell surface molecules such as the intercellular adhesion 
molecule 1 (ICAM-1) (193). 
 
ENDOTHELIAL CELLS: 
Angiogenesis is a key driver of psoriasis pathogenesis, evident by hyperproliferation of small 
dermal vessels in psoriasis skin (47). DMF has been shown to inhibit the expression of 
adhesion molecules such as E-selectin and vascular cell adhesion molecule-1  (VCAM-1) 
(194). DMF also causes a decrease in the formation of capillary-like structures in vascular 
endothelial growth factor (VEGF)-stimulated human endothelial cells, associated with a 
reduced expression of VEGF receptor 2 (195).  
 
Study rationale: 
Current oral systemic therapies, namely methotrexate, acitretin, and ciclosporin, are not 
effective in all of those with moderate to severe psoriasis and may cause adverse effects 
that require discontinuation of treatment. The next licensed step in treatment are expensive 
biologic treatments and more recently apremilast. Oral FAE are a cheaper alternative 
systemic therapy that are licensed in Germany, and recommended as first-line systemic 
agents for moderate to severe psoriasis in the European S3 guidelines (196). However, 
when we conducted our review, FAE were unlicensed in many other countries, which limited 
their clinical use and restricted the production of guidelines to assist patients and clinicians. 
For example, FAE are used to treat many individuals with psoriasis in the UK (118, 119), but 
when our review was conducted, no guidance existed from NICE or the BAD (NICE approval 
was issued in September 2017 (123), after publication of our review). This meant that there 
was no standardisation of prescribing schedules for oral fumaric acid esters, and many 
dermatologists chose not to consider their use for psoriasis because of the lack of guidance. 
Other factors that probably influenced prescribing FAE as an off-label medication were the 
cost of FAE in comparison to other systemic therapies such as methotrexate and acitretin, 
and physicians’ lack of experience with FAE and managing resulting adverse effects. As a 
result, inequalities existed in psoriasis care due to patient location. This review intended to 
assist in decision-making between patients and clinicians regarding choice of systemic 
therapy for psoriasis. 
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The study was registered with the Cochrane Skin Group (CSG). The plans for this review 
were published in the Cochrane Library as a protocol ’Oral fumaric acid esters for psoriasis’ 
(197). 
 
Funding sources: 
A grant was awarded by the Psoriasis and Psoriatic Arthritis Alliance (PAPAA) (Appendix 
10).  
 
Methods: 
Types of studies: 
We included randomised controlled trials, including cross-over trials. 
 
Types of participants: 
We included individuals of either sex and any age and ethnicity, with a clinical diagnosis of 
psoriasis made by a medical practitioner. We included all subtypes of psoriasis. 
 
Types of interventions: 
We included all randomised controlled trials that compared oral FAE, with or without another 
systemic or topical active treatment, with placebo or another active treatment: 
1. FAE versus oral placebo; 
2. FAE versus active treatment; 
3. FAE in combination with another active treatment versus placebo; or 
4. FAE in combination with another active treatment versus active treatment. 
We included studies that used any form of FAE, including Fumaderm®, the main 
commercially available preparation. 
 
Types of outcome measures: 
The study outcomes were specified in line with the Cochrane handbook for systematic 
reviews of interventions (198), which recommends no more than three primary outcomes. 
These should include at least one desirable and at least one undesirable outcome. A patient 
research partner was involved in selecting the outcomes at the protocol writing stage.  
 
Primary outcomes: 
 
1. Psoriasis Area and Severity Index (PASI) score: scale range from 0 (no disease) to 72 
(maximal disease). 
2. The proportion of participants who discontinued treatment due to adverse effects. 
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Secondary outcomes 
 
1. Quality of life score at follow-up measured with a validated scale. 
2. The proportion of participants attaining PASI 50, 75, and 90, defined as a 50%, 75%, or 
90% reduction in PASI score relative to the baseline PASI score immediately prior to 
treatment initiation. 
3. The proportion of participants experiencing nuisance adverse effects of treatment, i.e., 
non-serious side-effects that do not lead to treatment discontinuation. 
4. The proportion of participants experiencing serious adverse effects of treatment, defined 
as resulting in death, hospital admission, or increased duration of hospital stay. 
 
Timing of outcome measures: 
 
We included studies of any duration, but we planned to undertake a priori subgroup analysis 
to investigate the influence of duration of treatment. Studies were divided into short-term 
treatment duration (less than 12 weeks), medium-term duration (from 12 weeks to less than 
6 months), and long-term duration (6 months or greater). 
 
Economic data: 
 
We planned to incorporate health resource usage data, if provided, to place the clinical 
findings in an economic context. 
 
Search methods for identification of studies: 
 
We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language 
or publication status (published, unpublished, in press, or in progress). 
 
Electronic searches: 
 
We searched the following databases up to 7 May 2015: 
§ the Cochrane Skin Group Specialised Register using the search strategy in 
Appendix 11; 
§ the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane 
Library (Issue 4, 2015) using the strategy in Appendix 11; 
§ MEDLINE via Ovid (from 1946) using the strategy in Appendix 11; 
§ EMBASE via Ovid (from 1974) using the strategy in Appendix 11; and 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 38 
§ LILACS (Latin American and Caribbean Health Science Information database, 
from 1982) using the strategy in Appendix 11. 
 
Searching other resources 
 
Trials registers: 
 
We searched the following trials registers up to 14 May 2015 using the search terms 
’Fumaric acid’, ’Fumarate’, and ’Fumaderm’: 
§ The metaRegister of Controlled Trials (www.controlledtrials.com). 
§ The US National Institutes of Health Ongoing Trials Register 
(www.clinicaltrials.gov). 
§ The Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). 
§ The World Health Organization International Clinical Trials Registry platform 
(www.who.int/trialsearch). 
§ The EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/). 
 
Handsearching: 
 
In order to identify other potential RCTs for inclusion, two authors (AA and RA) 
handsearched the abstracts of proceedings from the following major dermatology 
conferences that were not already recorded in the Cochrane Skin Group Specialised 
Register: 
 
§ American Academy of Dermatology (AAD) (2008/2009); 
§ British Association of Dermatologists (BAD) (2008/2009/2010); 
§ European Academy of Dermatology and Venereology (EADV) (from 2006 to May 
2013); 
§ European Society for Dermatological Research (ESDR) (2005/ 2006/ 2007/ 2008/ 
2009); 
§ International Investigative Dermatology (IID) (from 2003 to May 2013); and 
§ Society for Investigative Dermatology (SID) (2007/2008/2009). 
 
References from included and excluded studies: 
 
We checked the reference lists of included and excluded studies for further references to 
relevant trials. 
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Correspondence: 
 
The first author (AA) contacted by email the corresponding authors of included and excluded 
FAE clinical trials to check for further unpublished RCTs. I corresponded with authors where 
necessary to determine if a study met the criteria for inclusion and to obtain additional data 
where necessary. 
 
Adverse effects: 
 
From the included studies identified, we examined data on adverse effects of the 
interventions. However, we did not perform a separate search for rare or delayed adverse 
effects. 
 
Data collection and analysis: 
 
Some parts of the methods section of this review uses text that was originally published in 
the Cochrane Handbook for Systematic Reviews of Interventions (198). 
 
Selection of studies 
 
Two authors (AA and RA) independently compared the titles and abstracts of the studies 
retrieved by the searches with the inclusion criteria. The full texts of studies that potentially 
met the criteria were examined, as well as the studies whose abstracts did not provide 
sufficient information. A third author (JI) resolved any disagreements in terms of final study 
selection. The reasons for exclusion of studies were recorded in the ’Characteristics of 
excluded studies’ tables (Table 4). 
 
Study Reason for exclusion 
 
Balak, 2015 (155) This trial did not meet the prespeciﬁed type of intervention. 50 participants were randomly assigned to 2 groups in 1:1 ratio. All participants received 
FAE, but 1 group received additional cetirizine 10 mg once daily whereas 
the other received additional placebo. The aim was to assess whether the 
addition of oral histamine H1 receptor antagonist to FAE would reduce the 
incidence of AEs 
 
Friedrich, 2001 
(199) 
The paper did not meet the prespeciﬁed type of intervention. 44 
participants were randomly assigned to 2 groups. All participants received 
FAE, but 1 group received additional pentoxifylline (PTX). The aim was to 
examine if addition of PTX reduced the risk of AEs 
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Gollnick, 2002 (200) The paper did not meet the prespeciﬁed type of intervention. 143 participants were randomly assigned to 2 groups. All participants received 
FAE, but 1 group had additional topical calcipotriol. The aim was to 
investigate whether the addition of calcipotriol had an additive efﬁcacy 
 
Nieboer, 1989 (146) The paper reported observations from 5 studies of which study 3 might have been eligible, but there was no evidence of randomisation 
 
Nieboer, 1990 (148) 
The paper did not meet the prespeciﬁed type of intervention. 45 
participants were randomly assigned to 2 groups. All participants received 
dimethyl fumarate (DMF), but 1 group had additional MEF. The aim was to 
assess the therapeutic efﬁcacy of DMF alone compared with combination 
of DMF plus MEF 
Table 4: Characteristics of excluded studies. AE: adverse effects; DMF: dimethyl fumarate; FAE: 
fumaric acid esters; MEF: monoethyl fumarate; PTX: pentoxifylline (from Atwan et al (201). 
 
Data extraction and management 
 
Two authors (AA and RA) independently extracted data using a data extraction form based 
on the ’Checklist of items to consider in data collection or data extraction’ found in the 
Cochrane Handbook for Systematic Reviews of Interventions (198). The following 
information from the reports of included studies were sought: study design and methodology, 
participants, interventions used, reported outcomes, selection bias, performance bias, 
detection bias, attrition bias, reporting bias, and any other sources of bias. A third author (JI) 
resolved any disagreements. Two authors (AA and RA) piloted the data collection form prior 
to use. The information collected was entered into the ’Characteristics of included studies’ 
tables (Table 5). 
 
Assessment of risk of bias in included studies: 
 
Two authors (AA and RA) independently assessed the risk of bias of the included studies 
using The Cochrane Collaboration’s ’Risk of bias’ tool (198). They graded the risk of bias as 
’low’, ’high’, or ’unclear’ for each of the following domains: 
§ random sequence generation (biased allocation to interventions due to inadequate 
generation of a randomised sequence); 
§ allocation concealment (biased allocation to interventions due to inadequate 
concealment of allocations prior to assignment);  
§ blinding of participants and personnel (performance bias due to knowledge of the 
allocated interventions by participants and personnel during the study); 
§ blinding of outcome assessment (detection bias due to knowledge of the allocated 
interventions by outcome assessors); 
§ incomplete outcome data (attrition bias due to amount, nature or handling of 
incomplete outcome data); 
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§ selective outcome reporting (reporting bias due to selective outcome reporting). 
For this Cochrane review, trial databases were checked to ensure that reported 
outcomes matched those prospectively listed; and 
§ other sources of bias (sources of bias that are relevant only in certain 
circumstances (e.g. recruitment bias in cluster-randomised trials) or particular clinical 
setting). 
 
Measures of treatment effect: 
 
For dichotomous outcomes, risk ratios with 95% confidence intervals (CIs) were pooled. For 
continuous outcomes, we combined either standardised or unstandardised mean differences 
with 95% CI, depending on whether different scales had been used and whether change 
scores were to be combined with follow-up scores. Follow-up scores rather than change 
from baseline were used as recommended by The Cochrane Collaboration (198). We 
planned to analyse ordinal data from short outcome scales using the methods for 
dichotomous data, by combining relevant adjacent categories to form a dichotomy. We 
planned to treat longer outcome scales as continuous data. 
 
Unit of analysis issues: 
 
The unit of analysis for our review was individual participants in the context that the 
intervention is a systemic treatment. We planned to permit the first phase of cross-over trials 
and pool the results with those from equivalent parallel group RCTs. For cluster-randomised 
trials, we planned to deflate the sample size using the design effect reported (198). 
However, we did not include any cross-over or cluster-randomised trials. 
 
Dealing with missing data: 
 
Whenever possible, AA made contact with the original trial investigators to request any 
relevant unreported data. If this was unsuccessful, we planned to attempt to impute standard 
deviations for a small proportion of the included studies. We planned to explore the impact of 
missing data through sensitivity analyses. For missing dichotomous outcome data, we 
planned to conduct two sensitivity analyses in which we would assume all missing data to 
be either events or non-events. 
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Assessment of heterogeneity: 
 
Statistical heterogeneity was assessed using the I2 statistic. We took a narrative approach 
and did not perform a meta-analysis if the value of the I2 statistic exceeded 75% because of 
considerable heterogeneity (202). An I2 statistic of between 40% and 75% may represent 
substantial heterogeneity (198), and we planned to explore the potential causes where 
possible for the primary outcome measures. 
 
Assessment of reporting biases: 
 
We planned to perform funnel plots and Egger’s test for publication bias (203) if 10 or more 
studies contributed data; however, we did not find sufficient studies to perform a funnel plot. 
 
Data synthesis: 
 
We dealt with the primary outcome ’PASI score’ as a continuous outcome (scale 0 to 72) 
whereas we handled the secondary outcome components, PASI 50, 75, and 90, as 
dichotomous outcomes. The latter represents the proportion of participants attaining 
50%, 75%, or 90% reduction in baseline PASI score, respectively. We reported pooled 
measures of effect with 95% CI and used a fixed-effect model because we expected 
reasonable similarity across the included studies that involved the same disease and similar 
treatments and study populations. We planned to highlight with detailed justification if we 
used a random-effects model during the analysis because of study heterogeneity. 
 
Subgroup analysis and investigation of heterogeneity: 
 
We planned to perform subgroup analyses on the following variables: 
§ treatment duration (short, medium, or long, defined as less than 12 weeks, 12 weeks 
to less than 6 months, or at least 6 months, respectively); and 
§ types of intervention and comparison (FAE versus placebo, FAE versus active 
treatment, etc.). 
 
Sensitivity analysis: 
 
We planned to perform sensitivity analysis for studies at higher risk of bias, determined by 
allocation concealment and blinding of outcome assessment. We planned to conduct two 
sensitivity analyses in which we assumed all missing data were either events or non-events. 
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Results: 
 
Results of the search 
 
The database searches identified a total of 80 records. Six additional records were identified 
by handsearching and 8 by searching the trials registers (Figure 14), giving a total of 78 
records after the removal of duplicates and ongoing studies. Two authors independently 
screened the titles and abstracts yielding 11 potentially eligible reports of studies. After 
obtaining the full texts of these reports, five studies were excluded (Table 4), and the 
remaining six were eligible for inclusion in the review. Two of the included studies were 
published in full reports (115, 204), one in a brief communication (205), one in a letter (206), 
and two as abstracts (207, 208). Full reports of published abstracts were not obtained by 
contacting the authors (see ’notes’ for Langner 2004 and Mrowietz 2006; Characteristics of 
included studies Table 5). 
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Figure 14: Study flow diagram (from Atwan et al (201)).  
 
 
Included studies:  
 
Six studies (115, 204-208) with a total of 544 participants met the inclusion criteria (Table 5).  
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Table 5: Characteristics of included srudies (from Atwan et al (201). 
Study author: Altmeyer 1994 (204) 
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Study author: Fallah Arani 2011 (115) 
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Study author: Langner 2004 (207) 
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Study author: Mrowietz 2006 (208) 
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Study author: Nugteren-Huying 1990 (205) 
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Study author: Peeters 1992 (206) 
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AE: adverse effects; BSA: body surface area; FAE: fumaric acid esters; GI: gastrointestinal; PASI: 
psoriasis area and severity index; PGA: physician global assessment; METC: medical ethics 
review committee; MTX: methotrexate; RCT: randomised controlled trial; SD: standard deviation. 
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Setting: 
 
Three of the included studies were carried out in the Netherlands (115, 205, 206), one in 
Poland (207), and two were international multicenter studies, all conducted in secondary 
care settings (204, 208).  
 
Participants: 
 
One trial was designed to measure the treatment effect in psoriatic arthritis (PsA), but 
contact with the author confirmed that all participants also had psoriasis (206). We included 
this study to obtain data on adverse effects (AEs). All of the included studies reported 
participants to be adults of at least 18 years of age except in Langner et al (207), which did 
not mention the age range of the participants. Two studies included only participants with 
chronic plaque psoriasis (115, 208); two included chronic plaque, guttate, pustular, and 
erythrodermic types (204, 207), but two studies did not report the type (205, 206). For 
participants to be eligible, 1 study (115) required them to have a Psoriasis Area and Severity 
Index (PASI) score ≥ 10 at baseline; 1 study (208) ≥ 12; and 1 study (207) 16 to 24. Two 
studies used body surface area (BSA) to assess severity for eligibility, being at least 10% in 
1 study, (205), and more than 10% in another (204). One study, which was specifically 
designed for PsA, did not include psoriasis severity for eligibility assessment (206). Fallah 
Arani et al (115) was the only study to provide details of previous psoriasis therapies, 
including phototherapy in 53%, conventional systemic agents in 61%, and biologic therapies 
in 7%. The wash-out period was four weeks prior to randomisation. 
 
Design: 
 
Four of the included trials had a two-arm parallel design, and of these, three compared oral 
fumaric acid esters (FAE) with placebo (204, 206, 208), and one compared FAE with 
methotrexate (115). One study had a four-group dose-finding placebo-controlled design 
(207), and one compared FAE versus octylhydrogen fumarate plus magnesium and zinc 
monoethyl fumarate (MEF) versus placebo (205). 
 
Interventions: 
 
There were some variations in the dose increments between studies. Four studies (115, 
204-206) used tablets containing a mix of dimethyl fumarate (DMF) and salts of MEF. The 
proportion of this mix was the same, containing 120 mg DMF and 95 mg MEF. The 
interventions in the other 2 studies were BG-12 (207) and Panaclar™, formerly BG00012, 
which contained 120 mg DMF (208). Low-strength tablets (containing 30 mg DMF) were 
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given in the first 2 weeks of the intervention in Altmeyer et al (204) and the first 3 weeks in 
Fallah Arani et al (115) whereas the other studies did not mention treatment initiation with 
low-strength tablets (205-208). In Altmeyer et al (204) the 120 mg DMF tablets dose 
increased by 1 tablet daily from week 3 to a maximum of 6 tablets daily, compared with an 
increase of 1 tablet weekly from week 4 in Fallah Arani et al (115) to a maximum of 6 tablets 
daily at week 9. Mrowietz et al (208) the dose was titrated over 7 days to the maximum dose 
of 720mg DMF (6 tablets). Two studies reported a gradual increase from one to six tablets 
daily with no further information (205, 206). Finally, Langner et al (207) provided no 
information regarding dose increments in the groups who received 360 mg and 720 mg DMF 
daily. In the one study that compared FAE with methotrexate (115), the methotrexate group 
started with an initial dose of 5 mg per week and then the dose gradually increased up to 15 
mg per week orally. After 12 weeks, the study gradually reduced the dose until stopping it 
after week 16. 
 
Outcomes: 
 
Timing of outcome reporting was of medium-term duration for all studies, namely at week 12 
(115, 207) or week 16 (204-206, 208). Not all trials reported on all outcomes prespecified in 
our review. The included studies reported the following outcomes: PASI score (115, 204, 
207, 208); proportion of participants who discontinued treatment because of adverse effects 
(115, 206); quality of life score (208); proportion of participants attaining PASI 50, PASI 75 
(115, 208), and PASI 90 (115); proportion of participants experiencing any AEs (115, 204); 
and proportion of participants experiencing serious AEs (115). None of the included studies 
reported data on economic evaluations. 
 
Risk of bias in included studies: 
 
Details of the ’Risk of bias’ assessment are provided in the ’Risk of bias’ tables in Table 5. 
Overall, there was insufficient reporting in most of the included studies to permit judgement 
of ’low risk’ or ’high risk’ (Figure 15; Figure 16). One reason is the publication type of some 
included studies, which included two abstracts (207, 208), one letter (206), and one brief 
communication (205). The fact that some studies were about 20 years old may also have 
influenced their incomplete reporting (204, 206). 
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Figure 15: ‘Risk of bias’ summary: review authors’ judgement about each ‘Risk of bias’ item 
for each included study (from Atwan et al (201)).  
 
 
 
Figure 16: ‘Risk of bias’ graph: review authors’ judgement about each ‘Risk of bias’ item 
presented as percentages across all included studies (from Atwan et al (201)).  
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Allocation: 
 
Only one study (115) reported adequate sequence generation and allocation concealment. 
The other studies did not report the method of sequence generation or allocation 
concealment. 
 
Blinding: 
 
Five of the six included studies were described as double-blind (204-208). Blinding of 
participants and personnel (performance bias) was of unclear risk in four of these studies 
and high risk in one (204). Blinding of outcome assessment (detection bias) was of low risk 
in one study (206), high risk in one (204), and unclear risk in the remaining three double-
blinded studies (205, 207, 208). The sixth study included in our review by Fallah Arani et al 
(115) had an open label design, so performance and detection biases were of high risk. 
 
Incomplete outcome data: 
 
Two studies had low risk of attrition bias (115, 206). This risk was unclear in the remaining 
four studies (204, 205, 207, 208). 
 
Selective reporting: 
 
The protocol of one study was prospectively registered (115). Slight variations between the 
registered protocol and published report was noted, but contact with the author confirmed 
that the relevant ethics committee had approved some minor changes after registering the 
protocol. High risk of selective reporting was observed in one study that mentioned PASI, 
Physician’s Clinical Global Impression, Patient’s Global Assessment, and Skindex-29 in the 
methodology, but only reported PASI in the results of the published abstract (207). The risk 
was unclear in other studies (204-206, 208). Funnel plots and Egger’s test were not 
performed to assess publication bias because fewer than 10 studies contributed data in our 
review. 
 
Other potential sources of bias: 
 
The risk of other potential sources of bias was low in one study (204), unclear in four studies 
(205-208), and high in one study (115), in which the dosing schedule of the comparator 
intervention (methotrextate) may have influenced the true efficacy results. 
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Effects of interventions:  
 
All of the included studies had a medium duration (12 – 16 weeks), so subgroup analysis for 
different treatment durations was not performed. Sensitivity analysis also was not performed 
because the risk of bias in the included studies was mostly unclear. Five studies compared 
FAE with placebo (Table 6), and one study compared FAE with methotrexate (Table 7). The 
two comparisons are displayed in separate ’Summary of findings’ (’SoF’) tables. 
 
A narrative approach was adopted to present the effects of FAE in the treatment of psoriasis 
because of a lack of opportunities for meta-analysis. Data from two reports comparing FAE 
with placebo were combined in a meta-analysis for one of the secondary outcomes, PASI 50 
(see Data and analyses). Of note, reduction in PASI score is a beneficial outcome, while 
PASI 50 refers to the proportion of participants achieving a 50% decrease in baseline 
PASI, so a higher PASI 50 represents greater treatment success. None of the included 
studies reported data on economic evaluations, so this was not possible to measure in our 
review. 
 
Comparison of oral fumaric acid esters with placebo 
 
Five studies compared FAE with placebo for the treatment of psoriasis (204-208), one of 
which was designed to measure the treatment effect in psoriatic arthritis (PsA) where all 
participants also had psoriasis (206). Three studies used a mixture of dimethyl fumarate 
(DMF) plus monoethyl fumarate (MEF) in enteric-coated tablets as an intervention (204-206) 
whereas the other two studies used DMF alone (207, 208). The prespecified outcomes were 
reported in some of the studies:  
- PASI score (204, 207, 208);  
- proportion of participants discontinued treatment because of adverse effects (206); 
- quality of life (QoL) score (208);  
- proportion of participants attaining PASI 50 and PASI 75 (207, 208); and  
- proportion of participants experiencing common nuisance adverse effects (204).  
 
The quality of the evidence was ’moderate’ for proportion of participants experiencing any 
common nuisance adverse effects; ’low’ for PASI score, quality of life, and proportion of 
participants attaining PASI 50 and PASI 75; and ’very low’ for proportion of participants who 
experienced adverse effects that led to treatment discontinuation (Table 6). 
 
The included studies did not report serious adverse effects, and it was unclear whether any 
of the adverse effects leading to treatment discontinuation were serious. A meta-analysis of 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 62 
results from 2 studies was possible for PASI 50 and PASI 75 data; however, only the PASI 
50 meta-analysis results are reported because of significant heterogeneity for the PASI 75 
data. Meta-analyses were not possible for all other outcomes, so these were reported in a 
narrative manner. 
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Primary outcomes:  
 
PASI score:  
 
Altmeyer et al (204) reported a reduction of PASI score from a mean of 21.57 at baseline to 
10.77 after 16 weeks of FAE treatment whereas in the placebo group, it remained constant. 
The study reported the difference between groups at week 16 to be statistically significant 
(P<0.0001). The text did not report mean PASI scores at baseline and week 16 for the 
placebo group. We attempted to obtain these values from the line graph provided in the 
study report by using a magnified Excel worksheet to read the values. This highlighted 
differences compared with the text of the report for the PASI scores relating to the FAE 
group. Attempts to contact the authors to seek clarification were unsuccessful, so on 
balance, we decided that the text values for the FAE group PASI scores were more likely 
to be accurate and avoided calculation of a mean difference with confidence intervals to 
prevent introduction of potential error into our review. 
 
Langner and colleagues (207) compared 3 doses of FAE (120mg, 360mg, 720mg) with 
placebo and reported the median percentage reduction from baseline PASI as 31%, 52%, 
71%, and 6%, respectively, after 12 weeks. The study reported this to be statistically 
significant for the 360mg and 720mg dose groups compared with placebo (P<0.001). The 
paper did not report mean PASI scores at baseline and follow-up. Similarly, Mrowietz et al 
(208) reported the median PASI score at week 16 in 2 groups that received either FAE 
(n=105) or placebo (n=70). The study reported the median score to be lower with FAE at 5.8 
compared with 14.2 with placebo (P<0.001), which represented a 67.8% and 10.2% 
reduction, respectively. The study also did not report mean PASI scores at baseline and 
follow-up, but reported an effect size of 7.4 (95%CI 5.40 to 9.40). 
 
The other two studies comparing FAE with placebo did not include a PASI score and instead 
measured the disease severity by estimating the body surface area (BSA) involved (205, 
206), “scoring the degree of infiltration and scaling of the plaques from 0 (no infiltration or 
scaling) to 8 (very severe infiltration or scaling)” (205), or scoring the degree of erythema 
and scaling on a scale range from 0 to 8 (206). 
 
Proportion of participants who discontinued treatment due to adverse effects: 
 
Only one study accounted for the number of participants who dropped out solely due to 
adverse effects (AE) (206). In this 16-week study, 2 participants from the FAE group (n=13) 
withdrew from the study (1 after 6 weeks because of diarrhoea that could not be controlled 
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by lowering the treatment dose and 1 after 12 weeks because of proteinuria and elevated 
serum creatinine levels, which were reversible several weeks after treatment 
discontinuation), compared with no withdrawals from the placebo group (n=14) (risk ratio 
(RR) 5.36, 95%CI 0.28 to 102.12; 1 study, 27 participants; very low-quality evidence) 
(Figure 17). However, these findings were uncertain because of indirectness and a very 
wide confidence interval. 
 
 
Figure 17: Comparison: FAE vs placebo; Outcome: AEs leading to treatment discontinuation 
(from Atwan et al (201)). 
 
 
Nugteren-Huying et al (205) reported that of the 39 participants equally randomised to 
receive FAE (DMF plus MEF), octylhydrogen fumarate plus magnesium and zinc salts of 
MEF, or placebo, 34 completed the study. The number of participants who completed the 
study in each group showed one dropout from the FAE group, three from the octylhydrogen 
fumarate plus magnesium and zinc salts of MEF group, and one from the placebo group, but 
the reasons were unclear. The study reported that all 13 participants in the FAE group had 
diarrhoea, and one experienced renal insufficiency. 
 
In another study by Altmeyer et al (204), the number of dropouts due to AEs alone was not 
possible to establish because FAE was terminated prematurely in 19 (38.8%) participants 
because of AEs (n=4), deterioration (n=5), and several reasons including “no change, 
increase in the extent and side effects” (n=10). In comparison, 29 (58.0%) in the placebo 
group withdrew because of worsening (n=22), gastrointestinal disturbances (n=1), and 
general dissatisfaction with treatment outcome (n=6). The two studies published in abstracts 
(207, 208) did not report the number of participants who completed the study and whether 
there were any dropouts due to AEs. 
 
Secondary outcomes: 
 
Quality of life (QoL) score: 
 
One study (208) reported quality of life assessment using Skindex-29 (range = 0 to 100; 
higher scores indicated a lower level of QoL). Mean Skindex-29 scores reduced from 54.7 at 
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baseline to 27.0 at week 16 in the FAE group (n=105) compared with a reduction from 54.0 
to 51.1 in the placebo group (n=70). This reduction correlated to a 47% improvement in 
quality of life with FAE with a reported between-group difference of -19.27 points (P<0.001). 
 
Proportion of participants attaining PASI 50, 75, and 90: 
 
The included studies reported PASI 50 and PASI 75 (207, 208). The number of participants 
who achieved PASI 50 was greater with FAE compared with placebo (RR 4.55, 95% CI 2.80 
to 7.40; P < 0.00001; I² statistic = 0%; 2 studies, 247 participants; low-quality evidence) 
(Figure 18). More participants on FAE therapy also attained PASI 75, but the results were 
not combined in meta-analysis due to substantial heterogeneity between these 2 studies (I² 
statistic = 77%). 
 
 
Figure 18: Comparison: FAE vs placebo; Outcome: PASI 50 (from Atwan et al (201)). 
 
 
Altmeyer et al (204) reported the change of PASI by calculating the remission index. This 
was categorised into bands different from the standard PASI 50, 75, and 90 as follows: > 
95%, 70 - 95%, 30 - 69%, < 30%, 0%, and < 0%; hence, we could not integrate these into 
the above calculations. The remaining two studies (205, 206) did not use PASI for severity 
assessment. 
 
Proportion of participants experiencing any adverse effects of treatment: 
 
Based on one study (204), the number of participants experiencing AEs was higher with FAE 
compared with placebo (RR 4.72, 95% CI 2.45 to 9.08; 1 study, 99 participants; moderate-
quality evidence) (Figure 19). The authors also stated the total number of times that an AE 
was reported, including multiple reports from the same participant. These included stomach 
ache or cramps (35 times versus twice), diarrhoea (27 times versus twice), flushing (21 
times versus none), skin burning (twice versus once), and itching (once versus none). 
Laboratory findings showed no change in haemoglobin and erythrocyte count, with no 
differences between groups or within groups. The study noted a mild decrease in leukocytes 
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at week eight in both groups with no changes thereafter. Although between-group analysis at 
week 16 showed no significant difference, within-group comparison showed a statistically 
significant decrease in the FAE group (P = 0.0163). The eosinophil count was unchanged in 
the placebo group, but increased in the FAE group from 2% (day 0) to 3.4% at 4 weeks (P < 
0.05), with a further insignificant increase to 4.7% at week 12. Eosinophilia at 28% was 
noted in 1 participant (unknown time point). Lymphocyte count was unchanged in the 
placebo group whereas the study reported a non-significant reduction in the FAE group 
between baseline and week 16. No significant changes were noted in platelet count or levels 
of bilirubin, urea, creatinine, glucose, alkaline phosphatase, transaminases, gamma 
glutamyltransferase (GGT), cholesterol, triglycerides, urinalysis, and creatinine clearance in 
either group. 
 
 
Figure 19: Comparison: FAE vs placebo; Outcome: common nuisance AEs (i.e. not leading to 
treatment discontinuation (from Atwan et al (201)). 
 
One study (206) reported diarrhoea, nausea, headache, and flushing as the most common 
side-effects in both FAE and placebo groups, but provided no numerical values to compute 
the difference. The study reported these adverse effects to be temporary in most participants 
and improved after reducing the dose or altering the dietary regimen (no further details). 
Within-group analysis showed a statistically significant reduction in the erythrocyte 
sedimentation rate (ESR) (P = 0.007) and alkaline phosphatase (P = 0.005) with FAE 
whereas haemoglobin, leucocytes, lymphocytes, platelets, and serum creatinine did not 
significantly change in either group. Comparison between the 2 groups showed statistically 
significant lower ESR in the FAE group (P = 0.02), lower leucocyte levels (P = 0.02), lower 
platelet levels (P = 0.02), and lower alkaline phosphatase activity (P = 0.005). However, as 
participants had psoriatic arthritis, the effect on these markers may not have been 
representative for individuals with skin psoriasis alone. 
 
In Nugteren-Huying et al (205), 3 groups were treated with FAE (DMF plus several types of 
MEF) (group 1 = 13), octylhydrogen fumarate plus magnesium MEF (5 mg) and zinc MEF (3 
mg) (group 2 = 13), or placebo (group 3 = 13). Group 1 reported the most common adverse 
effects as flushing (n=12), diarrhoea (n=13), fatigue (n=7), and nausea (n=6). One 
participant showed a rise of serum creatinine up to 238 umol/L and reduction of creatinine 
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clearance rate by 51%; this was reported to be reversible. Twelve participants in group 2 
developed diarrhoea as a main adverse effect. Group one (n=8) and group two (n=4) 
reported transient elevation of liver enzymes. Other abnormalities observed in group one 
were transient eosinophilia (five participants) and lymphopenia (four). The study provided no 
information about dropouts in the placebo group, and it was unclear which of the mentioned 
AEs led to treatment discontinuation in each group. 
 
Mrowietz et al (208) did not report the number of participants experiencing AEs. The abstract 
reported that 58% of FAE-treated participants compared with 23% of those receiving 
placebo had gastrointestinal AEs. Eighty-two per cent of these were classified as mild to 
moderate in severity (unclear if some, or all, of the remaining 18% dropped out because of 
severe symptoms). Forty-two per cent of participants reported flushing in the FAE group 
compared with 9% in the placebo group. There were no clinically relevant trends to abnormal 
values in haematology, chemistry, renal, or hepatic function studies. The study reported the 
AEs to be generally mild to moderate in severity and transient. 
 
Finally, Langner et al (207) reported that the most common AEs were flushing, minor plasma 
elevations of the liver enzyme alanine aminotransferase (ALT), common colds, and a low 
rate of gastrointestinal events (no numerical values provided to show if this was dose-
dependant or severe enough to cause treatment discontinuation.) 
 
Proportion of participants experiencing serious adverse effects: 
 
None of the studies reported whether any of the adverse events that led to treatment 
discontinuation were serious. 
 
Comparison of oral fumaric acid esters with methotrexate 
 
Only one study with an open label design compared FAE with methotrexate (MTX) (115). 
Reported outcomes included PASI score; proportion of participants who discontinued 
treatment because of AEs; proportion of participants who achieved PASI 50, 75, and 90; and 
proportion of participants experiencing common nuisance and serious AEs. The quality of 
the evidence for these outcomes was graded as 'very low' (Table 7).  
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Primary outcomes 
 
PASI score: 
 
After 12 weeks of treatment, the mean PASI score decreased from 14.5 (standard deviation 
(SD) 3.0) at baseline to 6.7 (SD 4.5) in the 25 participants treated with MTX compared with a 
reduction from 18.1 (SD 7.0) at baseline to 10.5 (SD 6.7) in the 26 participants treated with 
FAE. After adjustment for baseline values, the absolute difference (FAE minus MTX) at 12 
weeks was 1.4 (95% CI -2.0 to 4.7; P = 0.417). However, when we compared the PASI 
scores at follow-up (week 12), as recommended by The Cochrane Collaboration, this 
difference was in favour of MTX (mean difference (MD) 3.80, 95% CI 0.68 to 6.92; 1 study, 
51 participants; very low-quality evidence). However, this comparison does not take into 
account the baseline difference and so is unreliable.  
 
Proportion of participants who discontinued treatment due to adverse effects 
(AEs): 
 
Five of the 25 participants treated with MTX dropped out due to AEs (4 because of elevated 
liver enzymes and 1 because of recurrent angina) compared with 1 dropout in the 26 treated 
with FAE because of diarrhoea. This difference was not significant (RR 0.19, 95% CI 0.02 to 
1.53; 1 study, 51 participants; very low-quality evidence) (Figure 20). The study reported the 
elevated liver enzymes to be transient and normalised four to eight weeks after treatment 
cessation. 
 
 
Figure 20: Comparison: FAE vs methotrexate (MTX); Outcome: Adverse effects (AEs) leading 
to treatment discontinuation (from Atwan et al (201)). 
 
Secondary outcomes: 
 
Quality of life (QoL) score: 
 
Quality of life was not assessed in this study. 
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Proportion of participants attaining PASI 50, 75, and 90: 
 
There was no significant difference in the number of participants who attained PASI 50, 75, 
and 90 in the 2 groups. Eleven of the 26 participants treated with FAE and 15 of the 25 
treated with MTX achieved PASI 50 after 12 weeks (RR 0.71, 95% CI 0.41 to 1.22; 1 study, 
51 participants; very low-quality evidence) (Figure 21). Five participants who received FAE 
attained PASI 75 compared with 6 in the MTX group (RR 0.80, 95% CI 0.28 to 2.29; 1 study, 
51 participants; very low-quality evidence) (Figure 22), while PASI 90 was observed in 1 
participant in the FAE group and 2 in the MTX group (RR 0.48, 95% CI 0.05 to 4.98; 1 study, 
51 participants; very low-quality evidence) (Figure 23). 
 
 
Figure 21: Comparison: FAE vs methotrexate (MTX); Outcome: PASI 50 (from Atwan et al (201)). 
 
 
 
Figure 22: Comparison: FAE vs methotrexate (MTX); Outcome: PASI 75 (from Atwan et al (201)). 
 
 
 
Figure 23: Comparison: FAE vs methotrexate (MTX); Outcome: PASI 90 (from Atwan et al (201)). 
 
Proportion of participants experiencing any adverse effects of treatment: 
 
The number of participants experiencing adverse effects of treatments was not significantly 
different between the two groups. Whereas 24 of the 27 participants in the FAE group 
reported AEs, all 27 in the MTX group experienced AEs (RR 0.89, 95% CI 0.77 to 1.03; 1 
study, 54 participants; very low-quality evidence) (Figure 24). However, more participants 
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experienced flushing in the FAE group (13 versus 2) (RR 6.50, 95% CI 1.62 to 26.09). 
Participants in the FAE group reported influenza-like symptoms less commonly than those in 
the MTX group (1 versus 7), but this difference was not significant (RR 0.14, 95% CI 0.02 to 
1.08).  
 
 
Figure 24: Comparison: FAE vs methotrexate (MTX); Outcome: common nuisance AEs (i.e. not 
leading to treatment discontinuation (from Atwan et al (201)).  
 
There was no significant difference in reported laboratory findings between the two groups. 
Transient elevation of liver enzymes (100% to 200% of the values at screening visit) was 
observed in 3 of the 27 participants in the FAE group and 8 of the 27 participants in the MTX 
group (RR 0.38, 95% CI 0.11 to 1.26). There was transient eosinophilia (maximum 
measured level 1.55 x 10⁹ /L) in 5 participants in the FAE group compared with none of 
those in the MTX group (RR 11.00, 95% CI 0.64 to 189.65) and transient leucocytopenia 
(2.1 x 10⁹ /L) in 1 participant in the FAE group compared with none in the MTX group (RR 
3.00, 95% CI 0.13 to 70.53), and there were similar findings for lymphocytopenia. Transient 
thrombocytosis (with a maximum level of 422 x 10⁹ /L) was not noted in the FAE group 
compared with 1 occurrence in the MTX group (RR 0.33, 95% CI 0.01 to 7.84), and finally, 
an equal number of 8 participants from each group showed transient proteinuria (RR 1.00, 
95% CI 0.44 to 2.28). 
 
Proportion of participants experiencing serious adverse effects: 
 
This study reported that none of the participants experienced any serious or irreversible 
adverse effects. 
 
Discussion:  
 
The aim of this review was to provide the best available evidence on the efficacy and safety 
of oral fumaric acid esters (FAE) for the treatment of psoriasis. Six randomised controlled 
trials (RCTs), with a total of 544 participants, were included in this review. Five of these 
studies compared FAE with placebo. Data from these studies could not be pooled in meta-
analyses because of variations in reported outcomes and insufficient reporting; the only 
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exception was for PASI 50, which 2 studies reported. The meta-analysis included 247 
participants and demonstrated a combined PASI 50 of 64% for those given FAE compared 
with a PASI 50 of 14% for those on placebo, representing a number needed to treat to 
benefit (NNTB) of 2. This favourable NNTB result should be viewed in the context that PASI 
50 has been superseded by PASI 75 as the standard psoriasis outcome measure (64), and 
some have argued that in the era of biologic therapies, PASI 90 should be the treatment goal 
(209). Unfortunately, PASI 75 data in our review showed significant heterogeneity (I² statistic 
= 77%), so we did not combine these studies. 
 
Three of the studies reported statistically significant reduction of PASI scores with FAE when 
compared with placebo, but the mean difference could not be evaluated. The dropout rate 
due to adverse effects (AEs) was obtained from one study with uncertain findings due to 
indirectness, as designed for psoriatic arthritis, and a very wide confidence interval. One 
report indicated 47% improvement in quality of life (QoL) with FAE with a reported between-
group difference of -19.27 (P<0.001). Another study reported a significantly higher number of 
participants experiencing common AEs with FAE, mostly abdominal pain, diarrhoea, 
flushing, and eosinophilia. 
 
One of the included studies showed that the effect of FAE on PASI score was comparable to 
methotrexate (MTX) in terms of change from baseline. However, comparing PASI scores 
between groups at the endpoint showed favour of MTX due to a disparity in baseline disease 
severity between the two groups. The number of participants achieving PASI 50, 75, and 90 
was not significantly different, and dropout rates because of AEs were similar. The overall 
number of participants experiencing common nuisance AEs (not leading to treatment 
discontinuation) was not significantly different between the two groups; however, flushing 
was more likely for FAE compared with MTX. No serious AEs were observed in any of the 
participants, and unfortunately, the included studies did not assess the effects on 
participants' QoL. 
 
The small number of included studies and insufficient reporting of outcomes were major 
limitations to address the objectives of this review. Some studies included participants with 
various types of psoriasis, but the outcomes reported did not indicate whether the response 
to FAE varied between these different types. The majority of studies comparing FAE with 
placebo did not report the number of participants who completed the study or dropped out 
because of AEs. It was not possible to draw conclusions regarding whether the variations in 
dose increments had an impact on the magnitude of treatment effect or risk of AEs. We were 
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unable to establish if the use of dimethyl fumarate (DMF) alone has a similar efficacy and 
safety profile as the mixture of DMF plus monoethyl fumarate (MEF).  
 
Methotrexate (MTX) is used as a first-line oral treatment for psoriasis in many countries, so it 
was useful to compare MTX with FAE in one of the included studies. However, the maximum 
dose of MTX used in this study (15mg weekly) may have been suboptimal as higher doses 
are often administered in routine clinical practice and also the time of assessment at 12 
weeks might have been too brief to evaluate true efficacy. Although the study reported no 
significant difference in the percentage of participants who achieved PASI 75 and PASI 90 in 
week 16 after oral treatment was stopped, it must be noted that the dose of MTX was 
reduced gradually from week 12. So, it is unclear if this difference would remain insignificant 
if MTX was continued at the same dose. Unfortunately, none of the included studies reported 
long-term follow-up data; therefore, the long-term efficacy and safety of FAE could not be 
established from the included trials. Also, none of the included studies reported data on 
economic evaluations, so this was not possible to assess in our review. 
 
Data presented in this review was obtained from six reports, including two abstracts, one 
brief communication, and one letter. Incompletely reported studies present challenges for 
data extraction; however, we felt it was important to include them in this review because of 
the overall lack of eligible RCTs. Four studies presented PASI score as a primary outcome in 
different ways as mean scores at baseline and endpoint, percentage of median reduction 
from baseline, and median scores at endpoint. Insufficient reporting did not allow us to 
conduct multiple meta-analyses in order to draw robust conclusions. Overall, the evidence 
for reported outcomes was of low quality in studies that compared FAE with placebo and 
very low quality in those that compared FAE with methotrexate. It is worth noting that some 
of the included studies were conducted before the requirement for trial registration. Also, we 
were unable to perform funnel plot or Egger's test to assess the risk of publication bias 
because of the small number of included studies. 
 
To our knowledge, all of the studies related to this review were identified. In addition to 
electronic searches performed by the Trials search co-ordinator in the Cochrane Skin Group 
(CSG), one author (AA) searched other resources (including trial registers, handsearching, 
and grey literature). To minimise the possibility of missing reports, two authors (AA, JRI) 
independently screened the titles and abstracts to identify potential relevant studies. 
Following this, two authors (AA, RA) read the full papers of identified studies and extracted 
data from the eligible ones using the same data extraction form. The two authors resolved 
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discrepancies in 'Risk of bias' assessment between them or with the judgment of a third 
author (JRI) if they reached no initial agreement. When queries about included studies 
emerged, one author (AA) contacted study authors (please see 'notes' in Table 5). In some 
cases, no replies received, in part due to the length of time that had elapsed since the 
studies were performed. Advice was regularly sought from the Cochrane Skin Group (CSG) 
throughout the review process.  
 
It is worth noting that the use of different cut-off points for the PASI score (i.e., PASI 50, 75, 
and 90) is likely to be highly correlated with the absolute PASI score and therefore the 
update of this review (planned for 2020) should consider selecting only one of these 
outcomes. We planned to avoid meta-analysis if the value of the I² statistic exceeded 75%, 
so did not combine PASI 75 data from two reports (207, 208), although we concede that this 
is a somewhat arbitrary threshold for assessing heterogeneity, which may depend on several 
factors (section 9.5.2 – Cochrane Handbook for Systematic Reviews of Interventions (198)). 
 
Efficacy and safety data from non-Cochrane systematic reviews: 
 
Other non-Cochrane systematic reviews examining FAE for psoriasis were identified in the 
literature. Griffiths et al (94) conducted a review for treatments of severe psoriasis that 
included FAE. This review included five studies, two of which we excluded from our review 
(146, 148) (please see Table 2 for the reasons for exclusion). On the other hand, the 
Griffiths et al review (94) excluded Peeters et al study (206) as it was essentially designed 
for psoriatic arthritis rather than psoriasis. However, our contact with the author confirmed 
that all participants also had psoriasis and we therefore included this study in our review, 
mainly to obtain adverse effects data. 
 
The Griffiths et al review (94) dealt with variations in reporting of average PASI scores by 
dichotomising the response in terms of 'successful' or 'unsuccessful' treatment in order to 
report the treatment success rate as a risk difference (RD). This permitted a meta-analysis 
from which the authors concluded that FAE was superior to placebo with a pooled RD value 
of 0.47 (95%CI 0.33 to 0.61) (combined results of Altmeyer et al (204) and Nugteren-Huying 
et al (205)). This review performed no meta-analyses regarding adverse effects or other 
outcomes specified in our review. 
 
Mustafa and Al-Hoqail (210) performed a systematic review that included 21 RCTs reporting 
efficacy of systemic treatments for moderate to severe psoriasis. This review included 16 
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RCTs in meta-analyses where risk difference (RD) was reported to measure treatment effect 
whereas tolerability was assessed from rates of withdrawal and adverse effects. Although 
the review stated that it would study systemic treatments approved for moderate to severe 
psoriasis, it only reported results for biologics. The abstract of this review mentioned “Rates 
of withdrawals due to adverse events were highest for methotrexate and oral fumaric acid 
esters”, but the paper provided no relevant details. We contacted the author on 9 July 2014 
for clarifications and had received no response at the point of submitting this review. 
 
More recently, Schmitt and colleagues (8) conducted a systematic review to measure the 
efficacy and safety of systemic treatments, including biologics and conventional systemic 
therapies, for moderate to severe psoriasis. The review included only fully published RCTs 
and excluded review papers, letters, and abstracts. With regard to FAE, Schmitt et al 
included two studies (Altmeyer et al (204) and Fallah Arani et al (115)). The review found 
that FAE is superior to placebo based on mean PASI change and has similar efficacy to 
MTX (absolute risk difference 0.05, 95% CI -0.18 to 0.27) based on Fallah Arani et al report 
(115)), in agreement with the findings of our Cochrane review which calculated risk ratios. In 
keeping with our review, Schmitt et al review (8) reported that the rates of adverse effects 
and withdrawals did not differ between FAE and MTX but no statistical analysis was 
undertaken. 
 
Another systematic review by Ceglowska et al (211) in a conference proceeding reported 
clinical effectiveness of FAE for psoriasis and psoriatic arthritis. This review included three of 
our included studies (Altmeyer et al (204); Fallah Arani et al (115); and Peeters et al (206)), 
and presented the results in narrative form as in our review. It concluded that FAE have 
similar clinical efficacy to MTX in the treatment of moderate to severe psoriasis, based on 
the difference in mean change from baseline PASI score, and are more effective than 
placebo in the treatment of psoriasis and psoriatic arthritis. Measuring the efficacy of FAE in 
the treatment of psoriatic arthritis was not a prespecified outcome in our review. The 
Ceglowska et al review (211) did not examine the safety of FAE to compare with our 
findings. The quality of included studies in their review was scored from three to four points 
on the Jadad scale (range from zero, low quality, to five, higher quality). In comparison, our 
review determined the evidence to be of low quality when FAE were compared with placebo 
and very low quality when FAE were compared with MTX using the Cochrane GRADEpro 
tool. 
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The findings in our review reinforce the statement mentioned in the European S3 guidelines 
that "although the use of fumarates for psoriasis has been evaluated in clinical trials, only a 
small number of these have followed the criteria of evidence-based medicine" (99). The 
guidelines included a few open-label non-RCTs, which provided some data on the long-term 
safety of FAE; we did not include these in our review, which was restricted to relatively short 
RCTs. 
An observational prospective study by Walker et al (212) examined the effectiveness, 
dosing, and adverse effects of Fumaderm® in daily practice. Biogen Idec GmbH, the 
manufacturer of Fumaderm®, funded it. The study recruited 249 adult participants with 
psoriasis who started Fumaderm® during their routine clinical care from 78 German 
dermatology centres and followed them up at 3, 6, and 12 months. It was reported that mean 
PASI and DLQI scores in the study population decreased by 66.6% and 67.2% at 12 
months, respectively. In comparison, one of our included studies (208) reported 47% 
improvement in mean Skindex-29 score at 16 weeks, a much earlier endpoint. The Walker et 
al study (212) did not report PASI 50 at 12 or 16 weeks to allow comparison with our 
findings. Of the 249 participants in this report, 104 dropped out, but the study only 
documented reasons for this for 76 participants. Among these, 43.4% dropped out because 
of adverse effects. This rate was measured after 1 year of treatment whereas Peeters et al 
(206) and Fallah Arani et al (115) measured the dropout rates because of adverse effects at 
16 weeks and reported them as affecting 15.4% (2 of 13 participants) and 3.8% (1 of 26 
participants), respectively. 
 
Recent evidence for DMF in psoriasis: 
 
Following the publication of our Cochrane systematic review, Mrowietz et al (213) published 
the BRIDGE study, a three-arm randomised double-blind placebo-controlled non-inferiority 
trial including 671 participants with moderate to severe psoriasis. In this study, participants 
received either DMF (n=267), Fumadermâ (n=273) or placebo (n=131). The primary 
outcomes were the proportion of participants achieving PASI 75 and a score of ‘clear’ or 
‘almost clear’ in the Physician’s Global Assessment (PGA) at week 16. It was found that 
37.5% of those received DMF and 40.3% of participants on Fumadermâ achieved PASI 75 
(non-inferiority: P<0.001) but both interventions were superior to placebo (P<0.001). Both 
DMF and Fumadermâ had a similar occurrences of treatment-related AEs, commonly 
diarrhoea (DMF = 38.7%; Fumadermâ = 39.9%), upper abdominal pain (DMF = 20.1%; 
Fumadermâ = 22.6%) and flushing (DMF = 18.3%; Fumadermâ = 16.3%). The noninferiority 
margin between DMF and Fumadermâ in this study was set at 15%, so the results must be  
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interpreted with caution especially because of the lack of established MCID for PASI score.  
This study was funded by Almirall S.A., the manufacturer of the now approved DMF 
preparation, Skilarenceâ.  
 
Based on this study, DMF gained European Medicines Agency (EMA) (122) and NICE (123) 
approval for the treatment of moderate to severe psoriasis in adults. The NICE guidance 
recommends DMF as an option in those with severe psoriasis (PASI score of 10 or more) 
who have not responded to other systemic treatments including methotrexate, ciclosporin 
and PUVA, or if these are contraindicated or not tolerated (123). This implies that DMF is not 
a first-line systemic treatment and the eligibility criteria are comparable to biologic therapies. 
In part these recommendations were based on the available evidence from the BRIDGE 
study (213) in which PASI >10 and DLQI > 10 were eligibility criteria.  
 
 
Lymphopaenia and the risk of progressive multifocal leukoencephalopathy: 
 
Long-term safety of systemic therapies is an important factor to be considered by patients 
and clinicians. This could not be analysed from our Cochrane systematic review which 
included only short-term studies. One of the concerns with FAE treatment is the risk of 
prolonged lymphopaenia. The occurrence of this adverse effect cannot be estimated reliably 
from studies with small sample sizes. Also, in older studies lymphopaenia was measured 
according to different definitions (e.g. < 20% of the total leucocyte count (116); or > 50% 
reduction compared with baseline count (214)). The FUTURE study by Reich et al (215) 
examined the long-term efficacy and safety of FAE in 984 patients who received the 
treatment for a mean duration of 44 months in a retrospective fashion. Some of these (71%) 
received continuous treatment for at least 2 years whereas others had temporary 
interruptions for no longer than 6 months. Lymphopaenia was noted in 32% of patients after 
3 months of treatment, increasing to 41% in studied population after 24 months (Figure 25).  
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Figure 25: Percent of patients with change in blood count and other serum parameters during 
long-term treatment (from Reich et al (215)). 
 
Further data is provided by the BRIDGE study, an RCT involving 671 participants, showed 
lymphopaenia occurrence in 20.6% of patients who had FAE (n= 562) at week 16 (213). The 
lymphopaenia is not necessarily associated with leucopoenia, which was observed in 9% of 
patients at 3 months and maximally in 12% after 2 years (215). Interestingly, the status of 
certain genotypes of glutathione S-transferases (GSTs), a group of enzymes involved in 
xenobiotic detoxification, appeared to serve as a predictor for the occurrence of marked 
lymphopaenia in a study where 106 psoriasis patients were treated with Fumaderm® (216). 
Long-term FAE treatment did not appear to affect hepatic or renal function in the majority of 
patients where 96.1% of patients continued the treatment with no need for dose adjustments 
or treatment discontinuation (215). 
 
Before the approval of dimethyl fumarate (DMF) (Skilarence®) for the treatment of moderate 
to severe psoriasis in the UK and Europe in 2017, guidance on blood count monitoring was 
available for Fumaderm® (combined DMF plus MEF) via the Fumaderm Summary of Product 
Characteristics (SmPC) and the European S3-guidelines on the systemic treatment for 
psoriasis vulgaris (67, 99, 196). These recommendations indicated that blood test monitoring 
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should be performed at baseline and then every 4 – 8 weeks (weak consensus on 
frequency) (67). FAE should be withdrawn if leucocyte count drops below 3.0 x109 /L or if 
total lymphocyte counts is less than 0.5 x109 /L, whereas dose reduction is necessary if 
lymphocyte count is between 0.5 and 0.7 x109 /L. Guidance produced for Tecfidera® (DMF 
alone preparation licensed for the treatment of relapsing-remitting multiple sclerosis) 
recommended measuring leucocyte count at baseline and then annually, or as clinically 
indicated, and treatment should be withheld in patients with severe infections, but there was 
no guidance on managing leuco – or lymphopaenia (217). More recently, approval of 
Skilarence® came with clear guidance on blood count monitoring in patients receiving this 
treatment for moderate-to-severe psoriasis (218, 219), recommending treatment 
discontuation if lymphocyte level drops below 0.7 x109 /L (Table 8).  
 
 
Table 8: Blood test monitoring during dimethyl fumarate treatment (from Skilarence® Summary 
of Product Characterises (219))  
Blood monitoring in patients receiving FAE is particularly important as longstanding 
lymphopaenia, especially reduction in CD4+ T cells, may promote opportunistic infections 
and activation of latent infections (220). One such condition is progressive multifocal 
leukoencephalopathy (PML), a severe demyelinating disease of the nervous system caused 
by endogenous reactivation of John Cunningham virus (JCV). This polyoma virus typically 
causes an asymptomatic infection in childhood, usually in the first decade of life, resulting in 
circulating antibodies in 86% of healthy adults (219, 221). The virus remains latent in the 
kidneys and lymphoid organs but reactivation and spread to the brain can occur in the event 
of profound cellular immunosuppression (222). This infection develops almost exclusively in 
immunocompromised individuals. Patients with acquired immunodeficiency syndrome 
(AIDS) and idiopathic lymphopaenia for example have been observed to have higher 
incidence of PML (220). PML has also been reported in patients treated with certain 
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medications with immunosuppressive properties such as rituximab, natalizumab, efalizumab, 
and glucocorticoids (149). However, in some of these cases these therapies were used in 
combination with other immunosuppressants (e.g. cyclophosphamide, leflunomide and 
methotrexate) and others had underlying haematologic malignancy or collagen vascular 
disease (222). Drug-induced PML was noted to be less aggressive and usually not fatal, in 
comparison to HIV-associated PML (220). There is no specific treatment for PML but the 
main approach is to restore the host adaptive immune response (223). In HIV-related case, 
initiating or optimising antiretroviral therapy should be considered whereas stopping culprit 
immunosuppressive drugs is usually needed in drug-related PML. Treatment withdrawal may 
result in immune reconstitution inflammatory syndrome (IRIS) which may require 
methylprednisolone for a few days (149, 223). Mefloquine and mirtazapine are usually 
prescribed in those experiencing PML (149, 220, 223).  
 
The risk of PML with the use of FAE for psoriasis emerged in 2013 when three separate 
cases were reported in the New England Journal of Medicine. Two of these cases received 
Fumaderm® for 3 years (224, 225), while the third case had Psorinovo® (DMF alone 
preparation) for 5 years (226). Subsequently, the Medicines and Healthcare products 
Regulatory Agency (MHRA) issued a warning when a multiple sclerosis (MS) patient in 
Germany died due to PML following the use of Tecfidera® for 4.5 years with severe 
lymphopaenia for more than 3.5 years (227). These reports have increased clinicians’ 
awareness and several other reports were published in 2014-2015, describing PML in 
patients receiving FAE for either psoriasis or MS.  
 
In 2017, Balak et al (228) reviewed the literature with respect to PML in psoriasis and a total 
of 8 reported cases were identified (Table 9). The median age was 64 years (range 42 – 74 
years) and the median duration of FAE treatment (Fumaderm® in 6 cases and Psorinovo® in 
2 cases) was 3 years (range 1.5 – 5 years). All cases were linked to reduction of absolute 
lymphocyte counts, with nadirs ranging from 0.2 – 0.79 x109 /L for a median duration of 2 
years (range 1 – 5 years). Also, some of the reported cases had previously had 
immunosuppressive therapies such as steroids, methotrexate and efalizumab, or had other 
known risk factors for PML including malignancies. The most commonly reported 
neurological symptoms were aphasia (n=3), hemiparesis (n=3) and dysarthria (n=2). Other 
symptoms included hemiataxia, dysphagia, confusion, headache, apraxia and dysesthesia. 
All patients were managed by FAE discontinuation and started mefloquine and mirtazapine, 
leading to improvement in three patients and three patients had residual PML symptoms. 
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Five patients developed IRIS following FAE withdrawal, of whom one died due to 
complications.  
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In conclusion, regular monitoring blood tests are crucial to detect lymphopaenia at an early 
stage and it is important to follow the recommendations regarding treatment withdrawal in 
such cases to prevent the occurrence of PML in patients receiving FAE.  
 
Other systemic therapies: 
 
There are other systemic therapies for psoriasis and patients may have various factors 
influencing their treatment preference (e.g. safety profile, likely efficacy, speed of response). 
Bansback et al (234) reported in meta-analyses a RR of PASI 50 response of 4.74 with 
methotrexate 15-22.5mg weekly (95% CI 3.52 to 5.73), with an NNTB of 2; and 4.06 with 
ciclosporin 3 mg/kg per day (95% CI 2.54 to 5.73), with an NNTB of 2. These are 
comparable with our findings of FAE efficacy with a PASI 50 RR of 4.55 compared with 
placebo (95% CI 2.80 to 7.40) and an NNTB of 2. However, the dropout rates and risk of 
adverse effects were not reported by Bansback et al.  
 
Some of the best available evidence comparing efficacy and safety of conventional systemic 
agents (acitretin, ciclosporin, fumaric acid esters (FAE), methotrexate (MTX)), small 
molecules (apremilast, tofacitinib, ponesimod), anti-TNFa (etanercept, infliximab, 
adalimumab, certolizumab), anti-IL12/23 (ustekinumab), anti-IL17 (secukinumab, 
ixekizumab, brodalumab), anti-IL23 (guselkumab, tildrakizumab), and other biologics 
(alefacept, itolizumab) for patients with moderate to severe psoriasis has been recently 
reported in a Cochrane systematic review with network meta-analysis by Sbidian and co-
workers (235). This review included 109 studies involving 39,882 randomised participants. 
The primary outcomes were the proportion of participants achieving PASI 90 and 
experiencing serious adverse effects (SAE), while PASI 75, PGA 0 or 1, QoL measure, AE 
were all secondary outcomes.  
 
Endpoints from all trials included in the network meta-analysis were assessed 12 to 16 
weeks after randomisation. This review concluded that all interventions were significantly 
superior to placebo in terms of efficacy and not significantly different from placebo in terms 
of SAE. Anti-IL17, anti-IL12/23, anti-IL23 and anti-TNFa were significantly more effective 
than small molecules and conventional systemic therapies. The risk ratio (RR) for attaining 
PASI 90 with FAE compared with placebo was 4.09 (95%CI 1.88 to 8.88). This was 
comparable to MTX (RR 3.91 (95%CI 2.16 to 7.08)) and ciclosporin (RR 3.99 (95%CI 1.81 to 
8.78)). Acitretin on the other hand did not appear to be better than placebo for PASI 90 (RR 
0.98 (95%CI 0.06 to 17.24)). The chances of achieving PASI90 with apremilast was higher 
than all the conventional systemic agents (RR 7.66 (95%CI 4.30 to 13.66)).  
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With respect to PASI 75 in this network meta-analysis, FAE was ranked lower than other 
systemics when compared with placebo (RR for FAE= 2.64 (95%CI 1.64 to 4.25)); MTX= 
3.64 (95%CI 2.53 to 5.24); acitretin= 3.98 (95%CI 1.86 to 8.49); ciclosporin= 4.79 (95%CI 
2.84 to 8.09) the latter being similar to the small molecule apremilast (RR 4.85 (95%CI 3.60 
to 6.52)). It is worth noting that FAE data in this review was derived from a study where 
outcomes were measured at week 16, which may be too soon to evaluate the maximum 
treatment effect. 
 
The Sbidian et al Cochrane review has also shown that AE were more commonly noted with 
fumarates (RR 1.23 (95%CI 1.07 to 1.41) compared with ciclosporin (RR 1.16 (95%CI 0.93 
to 1.44) and MTX (RR 1.06 (95%CI 0.96 to 1.17). Again, these findings were on the basis of 
short-term treatment durations and as maintenance treatment is usually required for 
psoriasis, long-term safety should not be ignored. Although ciclosporin is a rapidly acting 
therapy in comparison to other conventional agents, long-term treatment is not 
recommended due to risks of nephrotoxicity and reduced renal function (236), and 
carcinogenicity (106). Also, both efficacy and nephrotoxicity have been demonstrated to be 
dose-dependent (5mg/kg/day vs. 2.5mg/kg/day) (105). Methotrexate on the other hand is 
hepatotoxic and long-term monitoring of liver function is needed. Occasionally, further 
investigations for liver fibrosis / cirrhosis are also needed. On the other hand, acitretin is a 
potent vitamin A analogue associated with dose-dependent xerosis and cheilitis, and is 
generally avoided in females of childbearing age due to long-lasting teratogenic effect after 
treatment discontinuation(107) 
 
Conclusion: 
 
Implications for practice: 
 
The results of this review should be interpreted with caution because of the relatively small 
number of participants treated in the qualifying RCTs and lack of meta-analyses due to 
outcome measure heterogeneity in the pre-PASI era when some studies were conducted. 
The limited data obtained from this review provide evidence that FAE are superior to placebo 
and may be similar in efficacy to MTX. Because of the different ways of reporting changes in 
PASI scores in studies comparing FAE with placebo, the magnitude of benefit could only be 
established for PASI 50. This was 4.5 times more likely to be achieved with FAE after 12 to 
16 weeks, with a NNTB of 2. The single study comparing FAE with MTX demonstrated a 
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similar reduction in mean PASI scores from baseline after 12 weeks, with a 7.6-point 
reduction for the FAE group compared with a 7.8-point reduction for those given MTX. 
Commonly reported adverse effects associated with FAE include gastrointestinal symptoms 
(58% of participants in 1 study), flushing (42%, 48%, and 95% in 3 studies), eosinophilia 
(18.5% and 38.5% in 2 studies), and reversible proteinuria (29.6% in 1 study). However, the 
RCTs examined did not report long-term follow-up data, so the review cannot comment on 
long-term safety of FAE for psoriasis, which is important because FAE may be taken for 
several years in routine clinical practice. 
 
Implications for research 
 
This review has highlighted several important gaps in the evidence base for the treatment of 
psoriasis with FAE. One of the main issues is outcome measure heterogeneity as some 
included RCTs were conducted prior to PASI and quality of life becoming the accepted 
efficacy measures for psoriasis. This will permit meta-analysis of efficacy data. Comparison 
with active controls, such as methotrexate, is to be encouraged because these are well 
established as effective, licensed systemic therapies. The relative efficacy of FAE compared 
with other systemic psoriasis therapies is also important to establish in the context of the 
relatively high cost of FAE in most countries.  
 
The included RCTs have not fully established the timescale in which FAE produce benefit in 
psoriasis. There is now consensus regarding gradual dose increments for FAE following 
treatment initiation (99), which should allow RCTs to compare speed of FAE action with 
other systemic therapies. Hence, an important future clinical trial would be a comparison of 
FAE with MTX both dosed using standardised increments and ensuring 12 weeks of 
treatment at the maximum dose prior to measuring the primary efficacy outcomes of PASI 75 
and quality of life, as well as clear reporting of treatment discontinuation due to adverse 
effects.  
 
This review also highlighted problems in the reporting of AE data, with much of this data 
either absent or not reported to Consolidated Standards of Reporting Trials (CONSORT) 
(www.consortstatement.org). Following these clinical trial standards and ensuring 
consistency in reported outcomes based on the Core Outcome Measures in Effectiveness 
Trials (COMET) initiative are necessary to enhance the quality and robustness of evidence 
(49). Following the schedule of dose increments according to the European S3 guidelines 
will allow an accurate measure of adverse effects associated with FAE and the rate of 
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treatment discontinuation because of these adverse effects. There is still a need to establish 
long-term safety of FAE with a large enough patient cohort to detect rare adverse effects; 
this evidence should be available in the relatively near future from registers of biologic 
interventions for psoriasis that contain a systemic medications arm, such as the UK British 
Association of Dermatologists Biologic Interventions Register (BADBIR) database (63). 
 
Dissemination of study results: 
 
Our full Cochrane review was published in the Cochrane Library (201) (Appendix 12) and co-
published in the British Journal of Dermatology (237) (Appendix 13).  
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CHAPTER 4  
Discussion and conclusion 
 
 
Two studies have been conducted in this research project with the aim of providing further 
evidence on improving psoriasis care through patients’ journeys from GP referrals to 
systemic therapy choices in secondary care. The first study explored the usefulness of 
quality of life (QoL) assessment when psoriasis patients are being referred from their GP to 
secondary care.  
Recognition of quality of life assessment is needed in psoriasis care: 
 
Quality of life is defined by the World Health Organisation (WHO) as “an individual’s 
perception of their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns” (238). 
Although there are different ways of measuring disease severity, such as disease extent and 
physical findings, these measurement domains do not quantify the extent to which the 
disease affects the patient’s wellbeing (239-241). Health is defined as “a state of complete 
physical, mental, and social well-being not merely the absence of disease”. Therefore, 
patient reported outcomes are integral part of measuring disease severity, and response to 
interventions. 
 
In our study we used the Dermatology Life Quality Index (DLQI) because it is the most 
widely used QoL instrument in psoriasis-related clinical trials (62) and clinical guidelines 
(64). It is accessible via the British Association of Dermatologists (BAD) and Cardiff 
University department of dermatology websites (242). There is no need to seek permission 
and there is no charge when using the instrument for routine clinical purposes (242). Another 
advantage of the DLQI questionnaire is that it is short, consisting of 10 tick-box questions 
and can be self-completed by patients in an average completion time of 2 minutes (59, 243).  
 
One of the challenges faced when conducting the study was difficulty engaging referring 
GPs to have the forms completed by their patients. This could be attributed to the fact that 
GPs have restricted consultation time and so with the time pressure forget or have 
insufficient time to give the questionnaire to patients. Another possibility is that lack of 
familiarity with the DLQI instrument led to concerns about additional consultation time. To 
mitigate for these potential concerns a DLQI teaching session was delivered to local GPs, as 
part of a regional cluster GP education meeting, including psoriasis severity assessment.  
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GPs have many questionnaires they are required to use in their routine practice and hence 
promoting the use of a new one was challenging. However, reassuring GPs that DLQI can 
be completed by patients before, after or during the consultation while they complete their 
own notes proved a helpful approach. Continuing professional development (CPD) sessions 
for practicing GPs could make use of the ‘Rule of Tens’ proposed by Finlay in 2005 (BSA > 
10; PASI > 10; DLQI > 10) (71), providing a simple and practical method that can be taught 
to GPs when assessing disease severity in patients with psoriasis.  
Psoriasis is a potentially stigmatizing condition with evidence of significant psychological 
impact including anxiety, depression and suicidal ideation (241, 244, 245). Despite this 
evidence, the psychological impact on patients is rarely addressed by clinicians (246). 
Studies have shown that psoriasis patients can be dissatisfied with their management and 
have unmet expectations (247-249). Nelson et al (250) conducted a qualitative study based 
on semi-structured interviews with 29 psoriasis patients. They concluded that patients felt 
their disease is complex with physical and psychosocial impacts which were largely 
unacknowledged by clinicians during consultations, both in primary and secondary care. 
Although the study included patients from different ethnic groups and ages, they were 
recruited from the community by direct advertising which raises the possibility of selection 
bias, as those with frustrating experiences may have been more likely to participate in the 
study. Still, these findings indicate that clinicians need to recognise and manage psoriasis as 
a complex long-term disease with physical, psychological and social impacts. So, using 
patient-reported outcome measure instruments, such as DLQI, is important at both primary 
and secondary care levels. 
 
Fumarates for psoriasis: 
 
When this research project was conducted, fumarates were used for the treatment of 
psoriasis in the UK as an unlicensed drug. Although a PIL was available on the BAD 
website, there was no clinical guidance on use of fumarates due to the lack of an EMA 
licence, arising in part from production issues and not being able to adhere to Good 
Manufacturing Practice in terms of the exact ratio of fumaric acid esters in the formulation. 
Therefore, we conducted a Cochrane systematic review to summarise the evidence for their 
efficacy and safety. Although non-Cochrane systematic reviews had been conducted to 
address this research area, a Cochrane systematic review was chosen to present the best 
available evidence. This is achieved because the process of conducting a Cochrane review 
is more robust and involves multiple levels of quality checks at protocol stage and when 
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results are generated. Statisticians, methodologists and clinical experts are involved in the 
peer-review of the study.  
 
This Cochrane review demonstrated a low number of RCTs investigating fumarates for 
psoriasis and found that most of the studies were old with unclear risk of bias and low-quality 
evidence. Our review concluded that fumarates were superior to placebo based on five 
RCTs. Only one study compared fumarates to an active comparator, methotrexate, in a 
head-to-head trial (115). This study concluded that both interventions were comparable in 
efficacy and safety but the study had a non-blinded design, producing high risk of 
performance and detection bias that resulted in the evidence being of very low quality (201). 
So, there is a need for well-designed double-blind trials comparing fumarates directly with 
methotrexate and other active standard interventions. 
 
Psoriatic nail changes and arthropathy are common findings in psoriasis patients but to date 
there is lack of evidence to support the role of FAE in their treatment. In a double-blinded 
placebo-controlled trial by Peeters et al (206), which was designed for PsA, those who 
received FAE (n=13) showed reduction in some parameters measuring arthritis compared to 
the placebo group (n=14) but the difference was not statistically significant. Roll and 
colleagues (143) recommend FAE for patients with psoriasis and mild PsA but those with 
more severe joint disease should be considered for other treatments, such as methotrexate 
or anti-TNFa. Long-term FAE treatment may result in some improvement in psoriatic nail 
disease after 4 months of treatment (214), but this was not assessed in controlled trials. 
 
A combined use of FAE with other anti-psoriatic treatments has been documented. The 
addition of topical calcipotriol resulted in increased FAE efficacy and quicker resolution of 
psoriatic plaques compared to FAE monotherapy (200). A report of 10 patients treated with 
FAE in combination with other systemic agents including ciclosporin, acitretin, methotrexate 
and hydroxyurea showed a reduction of the dose or treatment duration of the other drugs 
used (251). The exact duration of the combination therapy was not clearly stated. In 
contrast, a recent randomised exploratory study comparing etanercept monotherapy (n=14) 
vs. a combination of etanercept and fumarates (n=18) showed no statistically significant 
difference in terms of achieving PASI 75 effect after 24 weeks (252). Concomitant use of 
systemic therapies with FAE is not recommended in routine practice due to lack of safety 
data. The recently approved DMF preparation for psoriasis (Skilarence®) joined the BADBIR 
small molecules arm in March 2018 (253) so long-term efficacy and safety data from a large 
number of patients will be available in the future.  
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Real-world data about FAE for psoriasis: 
A prospective observational study by Walker et al (212) monitored 249 patients starting FAE 
in an outpatients setting at baseline, 3, 6 and 12 months and highlighted that PASI and DLQI 
scores continued to improve at 6 and 12 months, especially in those with severe and 
moderate-to-severe psoriasis (Figure 26).  
 
Figure 26: Reduction in PASI (left) and DLQI (right) scores in the study population from 
baseline (visit 1) at 3 months (visit 2), 6 months (visit 3) and 12 months (visit 4) (from Walker et 
al 2014 (212)). 
 
Similar long-term efficacy data was reported by Reich et al (215) in a retrospective study 
including 984 patients who received FAE continuously for a mean duration of 44 months. 
PGA assessment showed that after 3 months of therapy 30.8% of patients were “markedly 
improved” or “clear” and an additional 50% of patients “slightly improved”. After 6 months of 
therapy 67% of patients were “markedly improved” or “clear”; after one year this degree of 
improvement was documented in 76 % of patients and after 24 months 80% of patients were 
markedly improved or clear. In the subgroup of patients with recorded PASI score (n=107), 
the mean PASI score dropped from 22.7 at baseline to 4.8 after 36 months of treatment, 
representing 79% reduction (Figure 27). The retrospective design and the funding by Biogen 
Idec GmbH, the manufacturer of Fumaderm®, are potential sources of bias for this study. 
From the abovementioned long-term studies, it can be concluded that maximum efficacy of 
FAE should not be judged before 6 months of treatment. 
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Figure 27: Mean percent change in PASI score stratified according to baseline values (from 
Reich et al 2009 (215)). 
 
There are some pitfalls with FAE therapy. The fact that patients are required to take multiple 
tablets daily can lead to suboptimal treatment due to lack of adherence (214), which may be 
less of a problem with other conventional systemic therapies taken once or twice daily (e.g. 
acitretin and ciclosporin) or once weekly (e.g. methotrexate). However, it has been shown 
that the most patients on FAE therapy (70%) only require 2 to 3 tablets daily for long-term 
maintenance (212, 215). The gastrointestinal (GI) symptoms associated with FAE are 
common nuisance adverse effects; reported in 56% - 63.3% of patients (204, 213, 214). 
Although these are mild and transient in most patients, they can lead to treatment 
discontinuation in 3.8% - 7.7% of those starting treatment (115, 206, 214). Flushing is 
another adverse effect of FAE, reported variably in the literature in 34.6% - 55% of patients 
(116, 201, 213, 214). Eosinophila has been noted, also variably, in 15% - 38% of patients on 
FAE (116, 201, 213). This is mostly observed between the first and third month of treatment 
and no dose adjustment is needed (214, 215).  
 
A few published reports highlighted the use of FAE in children with psoriasis. In 2014, Steinz 
and colleagues (254) reported the efficacy of FAE in six paediatric patients treated at Kiel 
Psoriasis Centre. In this retrospective report, five girls and one boy with a median age of 
11.5 years (range 6 to 17 years) with moderate to severe psoriasis refractory to topical 
treatment or UVB were treated with Fumaderm®. The treatment duration ranged from 3 
months to 4 years and the dose was escalated in the same manner as in adults, following 
the German guidelines (196). The authors reported substantial response in all participants 
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after 12 weeks, achieving PASI75 (n=2), PASI90 (n=1) or PASI100 (n=3). However, these 
results in a small cohort need to be interpreted with caution; three of the treated children had 
guttate type psoriasis where PASI assessment is not reliable and spontaneous resolution is 
expected. Also, all patients were allowed concomitant use of topical steroids or vitamin D 
analogues if necessary, and four of the six children had tonsillectomy either one month after 
starting FAE (n=1) or at least 2 months before treatment initiation.   
 
Another retrospective paediatric case series from the Netherlands by Balak et al (255) 
reported the efficacy of FAE in 14 children and young people. The median age was 15 years 
(range 8 to 17) and all patients had chronic plaque psoriasis. The majority of participants 
(93%) had received prior phototherapy and / or systemic treatment. The standardised Dutch 
formulation of FAE was provided for a median duration of 10 months (range 1 to 80 months) 
with dose increments as in adults based on efficacy and tolerability. Five patients 
discontinued treatment after a median duration of 8 months (range 2 to 17 months) due to 
lack of response. Complete clearance was reported in 5 of the 14 patients (36%), one 
patient had had 82% reduction in PASI score after 4 months, and three patients had partial 
response after 6 months of treatment. Some of those remaining on the treatment 
experienced adverse effects included abdominal cramps (n=5), diarrhoea (n=4) and flushes 
(n=2) which were described as tolerable and transient in most cases but led to treatment 
discontinuation in two children after having treatment for 1 and 4 months because of 
abdominal complaints in one and severe flushing in the other.  
 
Overall, there is lack of high quality evidence for systemic options including FAE in refractory 
moderate-to-severe psoriasis in children and comparative studies in this age group are 
needed.  
 
Conclusion: 
 
Optimising the psoriasis care pathway is a multifaceted process that requires input from all 
healthcare professionals involved in psoriasis patient care. At the primary healthcare level 
GPs should be more aware of the impact of psoriasis on patients’ lives and use a validated 
quality of life instrument to measure this impact and ideally to improve the triage of psoriasis 
referrals to secondary care. One of the studies presented in this thesis shows a potential 
benefit of utilizing the DLQI as a triage tool to identify those individuals experiencing the 
greatest impact on their quality of life. In providing holistic care, healthcare providers are also 
expected to identify those with psoriatic arthritis or at risk of cardiovascular and metabolic 
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diseases so that early treatment can be initiated as primary or secondary prevention to 
improve the long-term health of patients.  
 
Systemic therapies for psoriasis should be selected on a case by case basis according to 
guidelines, patients’ comorbidities and their personal preferences. It is important that 
patients are fully aware of the available evidence to enable them to make informed 
decisions. Fumarates are one of the recognised systemic therapies for psoriasis. The 
Cochrane systemic review presented in this thesis demonstrates its superiority over placebo 
and possibly similar efficacy to methotrexate; however these findings were based on low-
quality evidence. Following the Cochrane review publication, dimethylfumarate was licensed 
by the EMA based on new trial evidence and approved by NICE as a third line systemic 
therapy for moderate-to-severe psoriasis. There is growing evidence that continued 
improvement on FAE occurs after the usual 12 – 16 week endpoints commonly used in 
trials. Therefore, long-term randomised clinical trials are needed to measure the true effect 
of FAE and its safety in direct head-to-head comparisons with other systemic treatments. 
Inclusion of FAE in pharmacovigilance databases will be important to assess rare, delayed 
adverse effects such as PML. 
 
Now, more than ever, psoriasis patients should be empowered to make decisions about their 
care in partnership with their clinicians, in the context of the increasing number of 
interventions available to treat psoriasis. Optimising the psoriasis care pathway includes 
ensuring that people with psoriasis are seen by dermatology secondary care services at the 
right time. In addition, people with psoriasis and their doctors need access to summaries of 
evidence for the different treatment options, a good source of which is provided by Cochrane 
reviews which combine a comprehensive meta-analysis with a plain language summary. 
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Appendices 
APPENDIX 1 
 
 
 
 
   DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
                                   DLQI 
 Patient code: …………..            Date:      /       /                                 Score:                                  
  
 Initials: …………… 
      
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER 
THE LAST WEEK.  Please tick þ one box for each question. 
 
1. Over the last week, how itchy, sore,    Very much r 
 painful or stinging has your skin      A lot  r 
 been?         A little  r 
         Not at all r 
 
2. Over the last week, how embarrassed   Very much r 
 or self conscious have you been because   A lot  r 
 of your skin?        A little  r 
         Not at all r 
 
3. Over the last week, how much has your    Very much r 
 skin interfered with you going     A lot  r 
 shopping or looking after your home or    A little  r 
 garden?              Not at all r Not relevant r 
 
4. Over the last week, how much has your    Very much r 
 skin influenced the clothes     A lot  r 
 you wear?       A little  r 
         Not at all r Not relevant r 
 
5. Over the last week, how much has your    Very much r 
 skin affected any social or      A lot  r 
 leisure activities?      A little  r 
         Not at all r Not relevant r 
 
6. Over the last week, how much has your    Very much r 
 skin made it difficult for      A lot  r 
 you to do any sport?      A little  r 
         Not at all r Not relevant r 
 
7. Over the last week, has your skin prevented  Yes  r 
 you from working or studying?    No  r Not relevant r 
  
 If "No", over the last week how much has    A lot  r 
 your skin been a problem at     A little  r 
 work or studying?      Not at all r 
 
8. Over the last week, how much has your    Very much r 
 skin created problems with your     A lot  r 
 partner or any of your close friends   A little  r 
 or relatives?        Not at all r Not relevant r 
 
9. Over the last week, how much has your    Very much r 
 skin caused any sexual      A lot  r 
 difficulties?       A little  r 
         Not at all r Not relevant r 
 
10. Over the last week, how much of a    Very much r 
 problem has the treatment for your   A lot  r 
 skin been, for example by making    A little  r 
 your home messy, or by taking up time?    Not at all r Not relevant r 
 
Please check you have answered EVERY question. Thank you.  
ãAY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors. 
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APPENDIX 3 
 
 
  
 
Patient Consent Form 
Version 1.0  27.04.2012          Original to be kept in study file.  1 copy for patient.  1 copy for hospital 
notes. 
1 
 
 
PATIENT CONSENT FORM 
Study Title:  
Optimising psoriasis referrals from primary care: Dermatology Life Quality Index 
(DLQI) as a triage tool 
 
Please initial each box to indicate that you have read and agree to each statement. 
1. I confirm that I have read and understand the information 
sheet, (version 1.0, dated 27.04.2012) for this study, that I 
have had the opportunity to ask questions and that I have 
received satisfactory answers to the questions I have asked. 
2. I understand that my participation is voluntary and that I am 
free to withdraw consent at any time, without giving any 
reason, without my medical care or legal rights being 
affected. 
3. I understand that sections of any of my medical notes may 
be looked at for the purposes of this study and by 
responsible individuals from regulatory authorities where it 
is relevant to my taking part in research.  I give permission 
for these individuals to have access to these records. 
4. I understand that anonymous data about me, as collected for 
this study, including information about my health may be 
used in publications about the study. 
5. I am happy for you to inform my GP that I shall be 
participating in this study. 
6. I agree to take part in the above study. 
 
__________________________       _______________         __________________ 
Name of patient Date  Signature 
(Please print your name and date your own signature) 
 
 
___________________________     ________________      ___________________ 
Name of person taking consent Date  Signature 
(Investigator)          
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APPENDIX 5 
 
 
  
 
1. Fredrickson T and Pettersson U. Dermatologica 1978; 157: 238-244 
Appendix 5 - PSORIASIS AREA AND SEVERITY INDEX (PASI)1 
 
Patient code number: _ _ _ Initials: _ _ _ _  Date: _ _ / _ _ / _ _ _ _  
 
SEVERITY OF PSORIATIC LESIONS 
 
Circle one number in each of the categories below: 
 
0 = None 1 = Slight 2 = Moderate 3 = Severe 4 = Very Severe 
 
  Head Upper Limbs  Trunk Lower Limbs 
1 Erythema 0    1    2     3     4 0    1    2     3     4 0    1    2     3     4 
 
0    1    2     3     4 
 
2 Thickness 0    1    2     3     4 0    1    2     3     4 0    1    2     3     4 
 
0    1    2     3     4 
 
3 Scaling 0    1    2     3     4 0    1    2     3     4 0    1    2     3     4 
 
0    1    2     3     4 
 
4 Total each column 
 
 
   
 
 
AREA OF PSORIASIS INVOLVEMENT 
 
5 Degree of Involvement 
0= None 1= <10% 2= 10 to < 30% 3= 30 to < 50% 
4= 50 to < 70% 5= 70 to < 90% 6= 90 to < 100%  
6 
 
Insert degree of 
involvement from 
Row 5 
 
 
 
   
7 
 
Multiply Row 4 
by Row 6 
 
    
8   X 0.1 X 0.2 X 0.3 X 0.4 
9 
 
Multiply Row 7 
by Row 8 
 
 
 
                 . 
 
                  
                 .                              
 
        
.  . 
 
       
       . 
 
ADD TOGETHER EACH COLUMN IN ROW 9                  .         = TOTAL PASI SCORE 
 
 
Assessor (print name please): ………………………………………………………………. 
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APPENDIX 11 
 
Skin Group Specialised Register (CRS) search strategy 
#1 ((psoriasis:MH OR psoria*) and (fumar* or dimethyl fumarate or fae or dmf or fumaderm)) AND(INREGISTER) 
[REFERENCE] [STANDARD] 
 
CENTRAL (the Cochrane Library) search strategy 
#1 MeSH descriptor: [Psoriasis] explode all trees 
#2 psoria* 
#3 #1 or #2 
#4 MeSH descriptor: [Fumarates] explode all trees 
#5 fumar* and esters 
#6 dimethyl fumarate 
#7 fae 
#8 dmf 
#9 fumarate* 
#10 fumaderm 
#11  
#12 #3 and #11 
 
MEDLINE (Ovid) search strategy 
1. exp Psoriasis/ or psoria$.mp. 
2. exp Fumarates/ 
3. (fumar$ and esters).mp. 
4. dimethylfumarate.mp. 
5. fae.ti,ab. 
6. dmf.ti,ab. 
7. fumarate$1.ti,ab. 
8. fumaderm.mp. 
9. or/2-8 
10. randomised controlled trial.pt. 
11. controlled clinical trial.pt. 
12. randomized.ab. 
13. placebo.ab. 
14. clinical trials as topic.sh. 
15. randomly.ab. 
16. trial.ti. 
17. 10 or 11 or 12 or 13 or 14 or 15 or 16 
18. exp animals/ not humans.sh. 
19. 17 not 18 
20. 1 and 9 and 19 
 
EMBASE (Ovid) search strategy 
1. exp psoriasis vulgaris/ or exp guttate psoriasis/ or exp erythrodermic psoriasis/ or exp psoriasis/ or exp pustular psoriasis/ 
2. psoria$.ti,ab. 
3. 1 or 2 
4. exp fumaric acid derivative/ or exp fumaderm/ or exp fumaric acid ethyl ester/ or exp fumaric acid dimethyl ester/ 
5. (fumar$ and esters).mp. 
6. dimethylfumarate.mp. 
7. fae.ti,ab. 
8. dmf.ti,ab. 
9. fumarate$1.ti,ab. 
10. or/4-9 
11. crossover procedure.sh. 
12. double-blind procedure.sh. 
13. single-blind procedure.sh. 
14. (crossover$ or cross over$).tw. 
15. placebo$.tw. 
16. (doubl$ adj blind$).tw. 
17. allocat$.tw. 
18. trial.ti. 
19. randomised controlled trial.sh. 
20. random$.tw. 
21. or/11-20 
22. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ 
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23. human/ or normal human/ 
24. 22 and 23 
25. 22 not 24 
26. 21 not 25 
27. 3 and 10 and 26 
 
LILACS search strategy 
(fumar$ or dimethyl fumarate or fae or dmf or fumaderm) and psoria$ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 128 
APPENDIX 12 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 129 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 130 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 131 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 132 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 133 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 134 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 135 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 136 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 137 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 138 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 139 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 140 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 141 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 142 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 143 
 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 144 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 145 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 146 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 147 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 148 
 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 149 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 150 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 151 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 152 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 153 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 154 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 155 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 156 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 157 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 158 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 159 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 160 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 161 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 162 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 163 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 164 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 165 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 166 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 167 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 168 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 169 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 170 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 171 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 172 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 173 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 174 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 175 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 176 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 177 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 178 
 
 
 
 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 179 
 
 
 
 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 180 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 181 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 182 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 183 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 184 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 185 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 186 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 187 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 188 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 189 
APEENDIX 13 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 190 
 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 191 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 192 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 193 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 194 
 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 195 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 196 
 
 
 
 
 
 
Optimising Psoriasis Care Pathway  Dr Ausama Abou Atwan (ID: 0636554) 
 197 
 
